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The architecture of chromatin is complex and plays a substantial role in all of the 
biological processes involving DNA. In particular, transcriptional activation depends on 
the interplay of dozens of chromatin modifiers to establish an epigenetic landscape 
permissive of gene transcription. Among the most dynamic histone modifications are 
the acetylation and methylation at histone 3 lysine 9, but the precise roles of their 
modifiers in conserved transcriptional programs remain unknown.  
 
Using the poly I:C-induced transcriptional response in MEFs as our model, we find that 
JMJD2d is a positive regulator of type I interferon responses. siRNA-depletion of the 
H3K9 demethylase JMJD2d attenuates gene activation and overexpression of JMJD2d 
potentiates the IFN response. We find that the underlying mechanism involves the 
activation of enhancers – knockdown of JMJD2d attenuates stimulus-induced enhancer 
activation, which is normally characterized by the accumulation of acetylated H3K9 and 
 
 
increased enhancer RNA transcription. In short, JMJD2d appears to control IFN 
responses by enabling the transition of enhancers from ‘poised’ (H3K9me3) to ‘active’ 
(H3K9ac) that allows for eRNA production. In support of this hypothesis, we observe 
that JMJD2d is tightly associated with enhancers in the genome and preferentially binds 
active enhancer regions. Taken together, JMJD2d represents the first example of a 
chromatin modifier with enhancer specificity and emerges as a potential therapeutic 
target in the modulation of IFN responses. 
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Chapter I: Introduction 
 
Host defense and stochastic type I interferon signaling 
 
Host defense is crucial to the survival of a species. In the type I interferon response, 
which is a central antiviral defense mechanism, IFN-α/β (IFN) is secreted to initiate a 
complex innate and adaptive immune response against bacterial pathogens and viruses. 
At the heart of this response is the coordinated activation of a specific transcriptional 
program. 
 
The first step leading to IFN activation begins with a signal from the cell surface or from 
the cytoplasm. Typically, the production of IFN is elaborated following recognition of 
viral nucleic acids by specific receptors that are either membrane-associated (TLR3, TLR 
7, TLR9) or cytoplasmic (RIG-I, MDA-5) (Bowie and Unterholzner, 2008). In endosomes 
and on specialized cells, the Toll-like receptor family consists of receptors with unique 
specificities. TLR3 recognizes dsRNA, TLR9 recognizes CpG dinucleotides, and TLR7 
detects ssRNA. Largely, TLRs are expressed in cells of the immune system, such as 
macrophages and dendritic cells. 
 
The cytoplasmic pattern recognition receptors (PRRs), by contrast, are ubiquitous, 
existing in almost all nucleated cells. RIG-I is responsible for the recognition of short 
dsRNA or ssRNA bearing a 5’ triphosphate group, while MDA-5 recognizes the viral 
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mimetic poly I:C (Stetson and Medzhitov, 2006). Heterodimers of RIG-I or MDA-5 form 
with exposure of a CARD domain that interacts with the same motif on IPS-1 on the 
mitochondrial membrane. Signaling networks downstream of IPS-1 lead to the 
activation of transcription factors such as IRF3, IRF7, NF-κB, and AP-130 that translocate 
to the nucleus and together aggregate in the IFN-β enhanceosome (Thanos and 
Maniatis, 1995; Panne et al, 2007). The coordinated activation of multiple transcription 
factors leads to the necessary and sufficient enhanceosome constituents, without which 
transcription of IFN-β will not proceed. 
 
This leads to subsequent docking of the GCN5 histone acetyltransferase complex 
(Agalioti et al, 2000). GCN5 engagement leads to the acetylation of histone 3 lysines 9 
and 14 and of histone 4 lysine 8, all within the nucleosome at the Ifnb1 promoter. , 
Nucleosomal remodeling follows, which results in recruitment of CBP-Pol II holoenzyme 
and subsequent transcription.  
 
Whereas many cells may ‘sense’ viral RNA, few will end up producing IFN itself. More 
specifically, the elaboration of type I interferons is known to be stochastic, with only a 
fraction of infected cells transcribing the gene. This is not a feature of genetic variation –
progressive subcloning of IFN-producing cells does not change the frequency of IFN 
production. Stochasticity is also not due to cell cycle variation, as synchronization 
experiments still show a minority of cells that respond. It is also not secondary to a 
failure of adequate sensing, as electroporation experiments with labeled poly I:C 
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recapitulate a stochastic rather than deterministic response occurring in a small 
percentage of cells. To date, this feature of the IFN response has been attributed to 
stochastic assembly of the enhanceosome, owing to the requirement that several 
transcription factors contemporaneously aggregate on the IFN-β promoter (Apostolou 
and Thanos, 2008). Recent evidence supports the notion that virtually every factor in 
the signaling downstream of cytoplasmic sensors is limiting, not just transcription 
factors. These include sensors for detecting viral nucleic acids (such as RIG-I and MDA-5) 
and intermediate signaling molecules (such as TRIM25 and IPS-1) (Zhao et al., 2008). It is 
the natural variation in the levels and activities of these proteins to which stochastic 
responses to poly I:C and viral infection has been attributed. 
 
Following the production of IFN-β, coordinated activation of a multitude of secondary 
genes, termed interferon-stimulated genes (ISGs) contribute to antiviral defense. Many 
of these ISGs are produced in response to transcription factors such as those belonging 
to the STAT and IRF families that lead to specific SWI/SNF-mediated nucleosomal 
remodeling at the ISG promoters and subsequent transcription (Ramirez-Carrozzi et al, 
2009). The antiviral response that ensues consists of several families of proteins, 
including the IFITs, the OAS family, and the MX proteins. Each of these IFN-inducible 
proteins have specialized effector functions. 
 
The Mx1 protein, for instance, has specific antiviral effects on influenza and VSV. A large 
GTPase that interacts with dynamin, Mx1, inhibits influenza virus infection by blocking 
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viral transcription and replication. The mechanism of its action is to inhibit the 
interaction between influenza nucleoprotein (NP) and polymerase basic protein 2 (PB2) 
(Verhelst et al, 2012). A second key protein is Ccl5, which plays an instrumental role in 
bridging innate and adaptive responses. Ccl5, also known as RANTES, functions as a 
chemokine to recruit T cells, eosinophils, and basophils to sites of antigenic challenge 
(Schall et al, 1990). In a similar vein, IFIT1 – strongly induced in the type I interferon 
response – acts as an inducible RNA sensor that has specificity for 5’ triphosphate ssRNA 
species (Pichlmair et al, 2011). Together, these examples of antiviral proteins highlight 
the diverse array of effector functions that IFN-inducible proteins execute. But the 
coordinated activities of these antiviral proteins in immunity cannot occur without 
precise transcriptional activation following the initial signal. 
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Transcriptional activation and chromatin 
 
First articulated in 1958 by Frances Crick, the ‘central dogma’ of molecular biology 
describes the flow of sequence information in the cell, beginning with DNA and ending 
with protein. However, that starting genetic material – DNA – is far more complex than 
Crick likely envisioned. DNA is wrapped around the nucleosome, an octamer of four 
histone proteins, and nucleosomes are then densely packed into higher-order fibers that 
together constitute chromatin. The architecture of chromatin is complex, and it plays a 
substantial role in all of the processes in which DNA participates, namely replication, 
recombination, cell division, and transcription.  
 
The complexity of chromatin is reflected both in its spatial organization and in its 
detailed structure. For a given gene locus, such as that of Ifnb1, a number of factors 
determine whether that small stretch of DNA can be transcribed. First, the type of 
chromatin it resides in matters. Broadly, chromatin exists as euchromatin or 
heterochromatin – two functionally distinct regions of the genome. Heterochromatin is 
tightly packed and inaccessible; euchromatin is less condensed and transcriptionally 
active. Moreover, these forms of genetic material are essentially segregated within the 
nucleus. Heterochromatin is restricted to the periphery of the nucleus, where there are 
extensive interactions with the nuclear lamina. Euchromatin occupies the center, where 
transcriptional factories can be found. 
 
6 
 
But for a locus to be transcribed, it is not enough to simply be in located in euchromatin. 
While broad spatial context within the nucleus is key, local factors are equally critical. 
Nucleosome density, for one, is crucial, as nucleosomes act as barriers to the RNA 
polymerase machinery. Alterations to this density are generated by nucleosomal 
remodeling initiated by complexes belonging to the SWI/SNF family, which modulates 
the accessibility of nucleosome-associated DNA. How the DNA itself is modified is 
important, as DNA can itself bear features that determine chromatin usage, such as CpG 
islands or methylation, both of which act to repress transcription.  
 
Importantly, the local context that determines transcriptional potential is the 
assortment of histone modifications that are present. The N-terminal histone tails on H3 
and H4, which protrude from the surface of chromatin and form ~25% of the histone 
mass, can be modified in a variety of ways (Strahl and Allis, 2000). To date, several 
modifications to histone tails have been described, including acetylation, 
phosphorylation, ubiquitination, ADP-ribosylation, sumoylation, deimination, proline 
isomerization, and methylation (Kouzarides, 2007). These occur on several different 
residues, including lysine (K), arginine (R), serine (S), threonine (T), tyrosine (Y), histidine 
(H), and glutamic acid (E) (Taverna et al, 2007). Together, the combinatorial pattern of 
these modifications has significant functional consequences, including recruitment of  
coactivators, eviction of nucleosomes by remodelers, and regulation of the accessibility 
of the transcriptional machinery.  
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This epigenetic landscape is dictated by dozens of chromatin-modifying enzymes. 
Broadly, the histone effector proteins that have been identified, each with their own 
substrate specificity, can be categorized as ‘readers’ - such as those containing 
bromodomains, chromodomains, and PHD fingers that recognize lysine acetylation, 
lysine 9 or 27 methylation, and lysine 4 methylation, respectively;  ‘writers’ – including 
various histone acetyltransferases and methyltransferases;  and ‘erasers’ – such as 
histone deacetylases and histone demethylases (Tarakhovsky, 2010). 
 
Together, these proteins can set and reset the epigenetic context in which a gene locus 
resides. Alterations to chromatin in the form of histone modifications generated by 
these readers, writers, and erasers have several consequences. For one, the manner in 
which histones are modified can directly impact the condensation of chromatin, as 
histone tails are known to be central to the folding process. The structural impact of 
histone modification, in turn, impacts the manner in which the central genetic processes 
involving DNA such as recombination, replication, and transcription proceed (Martin and 
Zhang, 2005). Specifically, lysine acetylation is known to disrupt the contacts between 
adjacent nucleosomes in the nucleosomal array by neutralizing the charge of the lysine, 
creating a chromatin environment wherein DNA is highly accessible (Berger, 2007). The 
second crucial consequence involves the impact on the ‘histone code’, wherein the 
unique pattern of modifications to histones determines its interactions with secondary 
proteins, which, in turn, mediate specific cellular responses (Jenuwein and Allis, 2001). 
The presence of histone 3 lysine 9 trimethylation (H3K9me3), for one, leads to the 
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accumulation of HP1α and HP1β isoforms and the formation of heterochromatin 
(Bannister and Kouzarides, 2005). By contrast, lysine acetylation of histones is primarily 
associated with activation of transcription by way of interaction with bromodomain-
containing proteins that, in turn, associate with P-TEFb that subsequent phosphorylates 
Pol II and allows for transcription (Jang et al, 2005). Indeed, each of the myriad histone 
modifications has an effect on transcription, and often these marks act in concert via 
engagement of effectors with multiple binding modules (Ruthenburg et al, 2007). 
 
Several associations have been elucidated with respect to the impact of a particular 
histone modification on transcription. As mentioned earlier, lysine acetylation – most 
commonly on H3 (K9, K14, K18, and K27) and H4 (K5, K8, K12, K16) – is associated with 
transcriptional activation. Similarly, serine/threonine phosphorylation, typically 
occurring in response to a proximal signaling event, is a mark associated with activation 
of the gene downstream of the promoter. Sumoylation is commonly linked to 
transcriptional repression, whereas arginine methylation leads to activation. In many 
instances, the mechanism by which the presence of a specific modification leads to an 
impact on the transcriptional machinery is unknown. Several possibilities exist, including 
physical inhibition of binding by either Pol II or other transcriptional components,  or by 
interaction with an unknown corepressor complex (Rosenfeld et al, 2006). 
 
Interestingly, the impact of lysine methylation on transcription is context-dependent, 
proving to be either an activator or repressor depending on the location of the lysine 
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residue at which is located and the number of methyl moieties there. Methylation at 
lysine 4 is invariably associated with transcriptional activation with the H3K4me3 mark 
found almost exclusively at the transcriptional start sites of active genes. This mark has 
been associated several effector molecules through CHD1, which itself is a member of 
large protein complexes that also feature histone acetyltransferases such as GCN5. This 
evidence establishes a link between the lysine 4 methyl mark and the transcriptional 
machinery by way of histone acetylation and its downstream effect on Pol II itself (Pray-
Grant et al, 2005). 
 
Both dimethylation and trimethylation of H3K9 are associated with transcriptional 
repression. H3K9me3 predominates in heterochromatin and also in the intragenic 
regions of active genes, whereas H3K9me2 is primarily located in repressed and silenced 
promoters. In a similar fashion, multiple methylation at H3K27 is associated with 
silencing, but is thought to represent a stable mark that remains in the absence of cell 
division (Tarakhovsky, 2010). Loss of methylation at lysine 27, as in the case of lysine 9, 
is associated with active promoters as they do not favor the association with the 
Polycomb chromodomain (PC) and HP1 proteins, respectively (Bannister and 
Kouzarides, 2005). On the other hand, persistent methylation at these residues is 
typically associated with transcriptional repression. 
 
Beginning with the identification of the first histone methyltransferase in 2000, several 
‘writers’ have been discovered that methylate the lysine and arginine residues on H3. Of 
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these, G9a, GLP, SUV39h1, SUV39h2, and SETDB1 have been identified as placing methyl 
groups on histone 3 lysine 9 (H3K9) in mammalian cells. G9a and GLP, are the major 
H3K9 methyltransferases responsible for placement of methyl groups in euchromatin 
(Tachibana et al, 2005). Histone methylation was initially thought to be irreversible 
enzymatically, a belief that was based primarily on observations demonstrating turnover 
rates of methyl groups on histones no greater than that of histones themselves (Shi and 
Whetstine, 2007). However, in 2004, lysine-specific demethylase 1 (LSD1) was 
discovered to have demethylase activity at histone 3 lysine 4, providing evidence for the 
dynamic regulation of histone methylation (Shi et al, 2004). Since then, several 
additional demethylases have been discovered, belonging to one of two distinct 
families. The first group employs an amine-oxidase domain mechanism and consists 
solely of LSD1, which demethylates H3K4 and H3K9, but the latter only in the context of 
its association with the androgen receptor (Mossamaparast and Shi, 2010).  Moreover, 
LSD1 is incapable of removing methyl groups from H3K9me3 (Metzger and Schule, 
2007). 
 
The second group of histone demethylases – the Jumonji family -- contains a Jumonji C 
domain and requires several cofactors, including Fe2+, O2, and α-ketoglutarate to 
hydroxylate the methyl group (Nottke et al, 2009). Owing to a different mechanism that 
does not depend on a protonated nitrogen, JmjC domain-containing demethylases can 
remove any methyl moiety from a given substrate; however, different Jumonji-
containing demethylases do bear differing specificities for particular marks. All told, 
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there are seven members of this group of enzymes (target residues in parentheses), 
including JMJD1a (H3K9me1/2), JMJD1b (H3K9me1), JMJD2a (H3K9me3), JMJD2b 
(H3K9me3), JMJD2c (H3K9me2/3), JMJD2d (H3K9me2/3), and PHF8 (H3K9me2) (Yamane et 
al, 2006; Whetstine et al, 2006; Fodor et al, 2006; Cloos et al, 2006; Shin and Janknecht, 
2007; Fortschegger et al, 2010). 
 
To date, several H3K9 demethylases have been implicated in developmental contexts. 
For example, JMJD1a, which specifically demethylates H3K9me2, is highly expressed 
during spermatogenesis and is required for chromatin condensation via demethylation 
of H3K9 at the promoters of Tnp1 and Prm1, two chromatin-packaging genes (Okada et 
al, 2007). Similarly, JMJD1a and JMJD2c appear to be crucial for the maintenance of 
embryonic stem cell pluripotency, as both are activated by the transcription Oct4. Stable 
knockdown of either of these demethylases leads to downregulation of the pluripotency 
factors Oct4, Sox2, and Nanog, as well as loss of ES cell morphology in culture (Loh et al, 
2007). As such, there is considerable evidence implicating the H3K9 demethylases in 
differentiation and development. 
 
H3K9 demethylases have also been associated with metabolic function, as in the case of 
JMJD1a. Mice lacking JMJD1a are markedly obese and hyperlipidemic relative to their 
littermates, a phenotype linked to the nuclear hormone receptors PPAR-γ and RXR-α 
(Tateishi et al, 2009). The authors show specific demethylation by JMJD1a of the PPAR 
responsive element of the Ucp1 gene facilitating hormone receptor recruitment. In the 
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absence of JMJD1a, the expression of metabolic genes is impaired, as is β-oxidation and 
glycerol release in skeletal muscle. Finally, JMJD2a and JMJD2d interact with the 
androgen receptor (AR), and in the absence of the latter there is reduction in the 
transcription of prostate-specific antigen in LNCaP prostate cancer cells (Shin and 
Janknecht, 2007). Until recently, little else was known about the Jumonji family than 
these few reports. 
 
How does this complexity of chromatin affect the type I interferon response? The 
interplay and balance between histone-modifying enzymes of opposing function confers 
on chromatin an inherent plasticity that can dramatically affect the transcriptional state 
of a cell. In immune responses, this plasticity is exploited to allow for a vast but precise 
array of genes to be simultaneously activated or repressed; in other words, the state of 
chromatin is altered to initiate the transcriptional programs central to innate immunity. 
This means that all of the coordinated events required for transcription must occur. 
Histone ‘writers’ must place active marks, ‘erasers’ must  remove repressive marks, and 
‘readers’ must read the new landscape that has been generated. The changes occurring 
in the vicinity of promoters and transcriptional start sites (TSSs) were originally thought 
to primarily determine gene activation. However, recently, considerable data suggest 
that gene activation is preceded by a similar set of epigenetic events occurring at 
enhancers. 
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The role of enhancer chromatin in gene expression 
 
Over the last few years, it has become increasingly clear that cis-regulatory elements 
play a critical role in the activation of gene transcripts. Among the myriad regulatory 
elements – enhancers, silencers, insulators – enhancers are most noteworthy, as these 
genomic regions appear to control gene expression of loci that can be great distances 
removed from the enhancer itself. Like promoters and genes, enhancers are also 
chromatinized regions but have unique features. They are characterized by high DNase I 
accessibility, the presence of coactivator proteins, and monomethylation of histone H3 
lysine 4 (H3K4me1) (Calo and Wysocka, 2012). Initial profiling of enhancers using ChIP-
chip methods revealed a diverse array of regulatory elements in the human genome, 
more varied across cell types than promoters themselves (Heintzman et al, 2009).  
 
Chromatin states at these enhancers have become increasingly well-characterized 
beyond the initial finding noting the ubiquitous presence of H3K4me1. H3K4me3 is 
notably absent from these regions, thereby distinguishing them from promoters. 
H3K27ac is also frequently associated with enhancer regions, where it is a mark of 
enhancer activity. Additional histone modifications have since been described as being 
present, including H3K27me3, H3K9ac, and H3K9me3 (Zentner et al, 2011; Rada-Iglesias 
et al, 2011). Indeed, the spectrum of histone modifications parallels those observed at 
promoters.  
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Nucleosomes are also different at enhancer regions than they are elsewhere. Overall, 
these regions are relatively nucleosome poor, as indicated by the DNase I 
hypersensitivity. Second, unique histone variants can be deposited, such as histone H3.3 
and H2A.Z – with the double-variant being found primarily at enhancers (Jin et al, 2009). 
These nucleosome core particles are mobile and highly salt-sensitive such that enhancer 
DNA is relatively accessible. 
 
Together, the landscape of modifications at enhancers, similar to promoters, is what 
dictates their functional state. All enhancers are typically associated with H3K4me1 and 
are absent of H3K4me3. The remaining modifications, however, vary with level of 
enhancer activity. Active enhancers are enriched with the coactivator CBP/p300 and 
have high levels of H3K27ac, H3K9ac, and H3K36me3), while poised enhancers have 
H3K27me3, H3K9me3, and lack H3K36me3. These latter enhancers may have lower levels 
of enrichment with p300 as well. Of note, genes proximal to active enhancers are 
typically more highly transcribed than those proximal to poised enhancers, suggesting 
that  differences in histone marks at these enhancers correlates with their activity.  
 
Enhancer chromatin is notable in that it too is transcribed. A significant amount of 
extragenic Pol II has been seen to accumulate at these regulatory elements, specifically 
in macrophages in response to LPS (De Santa et al, 2010). In another line of evidence, 
neurons were noted to accumulate enhancer RNA (eRNA) transcripts in response to 
depolarization with potassium chloride (KCl) (Kim et al, 2010). The amount of eRNA 
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correlated with nearby mRNA expression, connecting the transcription of enhancers 
directly with target gene activation. Generally, eRNAs are either short, bidirectionally 
transcribed, and not polyadenylated or can be longer, unidirectional, and 
polyadenylated. Transcription proceeds from the enhancer center (at the p300 peak) 
and proceeds to the termination of the H3K4me1 region (Natoli and Andrau, 2012). In 
sum, we now know that active enhancers, in addition to the histone marks described 
earlier, are also enriched in Pol II and more frequently transcribed; on the other hand, 
poised enhancers, with largely repressive marks, have less Pol II and less eRNA. 
 
Active histone marks, Pol II occupancy, and eRNA transcriptions are hallmarks of the 
active enhancer. These features all correlate with transcription of the nearby gene. But 
how exactly does an active enhancer facilitate transcription of a gene? Prior to 
transcription, enhancers first act as an integrated binding platform for upstream signals. 
Various transcription factors bind to these enhancers at transcription factor binding 
sites (TFBSs), which is followed by the recruitment of coactivator proteins. These 
coactivators may include the histone acetyltransferases (such as CBP/p300 or 
GCN5/PCAF) that generate the ‘active’ enhancer pattern, the chromatin remodelers 
(that can evict nucleosomes), and the mediators between enhancer and promoter (such 
as cohesin and Mediator) (Calo and Wysocka, 2012). Coactivator engagement is 
followed by recruitment of the polymerase machinery to the enhancer and subsequent 
transcription.  
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What follows next remains largely unknown, though the mechanism by which eRNA 
leads to mRNA is thought to be related to either ‘looping’ of the DNA or ‘tracking’. In 
either mechanism, enhancers are instrumental in the delivery of both the transcriptional 
machinery and the chromatin modifiers (such as nucleosome remodelers and 
coactivators) to the target gene. The ‘looping’ model posits that the enhancer ‘folds’ 
over on to the promoter such that a loop forms thereby excluding the intervening 
stretch of DNA. The ‘tracking’ model asserts that the recruited machinery translocates 
linearly along the DNA. However it occurs, it appears that enhancer activation and 
transcription are antecedent events that precede and facilitate the transcription of a 
gene.  
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Control of transcriptional responses and enhancer activity by H3K9 trimethylation 
 
Given the conserved transcriptional response that occurs in type I interferon signaling, 
we looked to further our understanding of enhancer chromatin examining nucleic acid 
sensing in MEFs. Specifically, we sought to determine a role for modifiers of the histone 
3 lysine 9 residue in this system, either at promoters or at enhancers. Our hypothesis is 
that H3K9 enzymes must be central to gene activation, as modifications on the K9 
residue on histone H3 are highly dynamic in transcriptional responses.  
 
This hypothesis is rooted in multiple lines of evidence. First, unpublished data from our 
laboratory suggested a demethylation event might occur at the IFN-β promoter in 
response to an upstream signal. Second, the Blobel lab had demonstrated that gene 
bodies dynamically accumulate H3K9me3 in gene bodies that is cotranscriptionally 
deposited (Vakoc et al, 2006). This H3K9me3, despite engagement with HP1γ, is rapidly 
removed as well. Third, vascular smooth muscle cells from diabetic mice were shown to 
exhibit a persistent inflammatory phenotype in vitro with continued expression of IL-6, 
MCP-1, and M-CSF. Subsequent ChIP analysis showed significant reduction in H3K9me3 
at the promoters of these cells compared to cells from wild-type mice. Furthermore, 
treatment with TNF-α led to an increase in the transcription of these genes that was 
associated with further demethylation of H3K9me3 at their promoters (Villeneuve et al, 
2008).  
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Given this evidence, histone 3 lysine 9 modifiers posed a promising avenue for 
investigation. Our hypothesis at the outset was that one of the H3K9 demethylases 
would be central to antiviral signaling via demethylation of repressed promoters or 
poised enhancers. 
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Chapter II: Stochastic activation of IFN-β and the histone demethylase JMJD2d 
 
Chromatin dynamics and enhancer transcription in the innate immune response 
 
In the antiviral response, key transcriptional programs are activated to effect the 
expression of genes that are critical for host defense. Expression of innate immune 
response genes is the outcome of coordinated chromatin events that culminate in 
initiation and elongation by RNA polymerase II.  Some of these chromatin events are 
well-characterized, such as the accumulation of H3K4me3 and acetylated H3 and H4 
residues at nucleosomes in the vicinity of transcribed gene promoters. However, the 
spectrum of chromatin changes in the innate immune response that occur throughout 
the epigenome, and specifically at enhancer chromatin, has not yet been described.  
 
To ascertain the modifications that occur at enhancer chromatin, we began by isolating 
mouse embryonic fibroblasts (MEFs) from wild-type mice and characterizing the 
transcriptional program that is activated in response to the synthetic dsRNA analog, 
polyinosinic:polycytidylic acid (poly I:C). Following four hours of in vitro stimulation, we 
detected the expression of 113 genes (Table 1) consisting of several type I interferons 
and interferon-stimulated genes (ISGs). Several of these gene products detected by 
gene array were confirmed by reverse transcription-quantitative polymerase chain 
reaction (RT-qPCR) (Figure 1). In vitro stimulation of MEFs with poly I:C was repeated 
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Table 1. The transcriptional response activated to poly I:C stimulation in MEFs. Wild-
type MEFs were stimulated with poly I:C and RNA was isolated after four hours. 
Microarray analysis was performed; shown are genes upregulated > two-fold. Data are 
the average of three independent experiments. 
 
Gene Fold induction Gene Fold induction 
Cxcl10 31.605846 BC006779 3.122934 
Ifnb1 28.197994 Hist1h4i 3.0815237 
Mx2 21.680067 Zfp36 3.0594335 
Ifit3 17.80783 Slc2a6 3.0403197 
Ccl5 15.489736 Dusp8 2.954846 
Usp18 13.926942 Phlda1 2.920562 
LOC100048346 13.258817 Egr2 2.9192994 
Ccl2 10.3806505 Jun 2.9140236 
Rsad2 9.976725 Oas1g 2.867266 
Gbp3 9.908558 Dhx58 2.8625565 
Gbp2 9.564882 Gadd45a 2.8510737 
LOC667370 9.257187 Ifi47 2.800076 
Tnfaip3 9.252282 LOC100047963 2.7851608 
Ifit3 8.9953575 Klf6 2.7642763 
Iigp2 8.912015 Hist1h4f 2.7262323 
Cxcl1 8.762168 Fos 2.628029 
Gbp3 8.508837 Ier3 2.5963612 
Igtp 8.133124 Ddx58 2.5943835 
Cxcl9 7.614855 Hdc 2.57001 
Irf1 6.723368 Slc25a25 2.5684092 
Irf1 6.712335 Ripk2 2.5577598 
Egr1 6.355163 Ccrl2 2.5141284 
Icam1 6.2216988 Josd3 2.4459813 
Oasl2 6.16569 Klf2 2.4446518 
Ccl7 5.59689 Txnip 2.4422612 
LOC100038882 5.524834 Il15 2.4303243 
Oasl1 5.513505 Hist1h2ac 2.4291928 
Axud1 5.478931 Zc3h6 2.4050522 
Tlr2 5.2830234 D14Ertd668e 2.3843863 
Irgm1 5.151454 1500012F01Rik 2.3809233 
Trim21 5.1163 Trex1 2.340291 
Usp18 5.07427 Relb 2.3122492 
Parp14 5.0238853 Irf9 2.3026154 
Chac1 4.8086157 Klf6 2.2975144 
Atf3 4.635319 Eif2ak2 2.2964149 
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Gene Fold induction Gene Fold induction 
Samd9l 4.5879884 Hap1 2.2832747 
Cd274 4.513661 Plekha4 2.2785983 
BC006779 4.3705626 Hist1h4j 2.2728412 
Stat2 4.22059 Ccrn4l 2.2654698 
Irf1 4.216204 Ube1l 2.2620642 
Apol9b 4.131248 Gadd45a 2.2534916 
Irf1 4.1279507 Ccrn4l 2.2346642 
Hist1h2bj 4.1037383 Irf7 2.2253335 
Junb 4.0334687 Daxx 2.2144337 
Gbp6 3.9819858 LOC100046232 2.1916113 
Gadd45g 3.976631 Ppm1k 2.1887937 
Hist1h2bh 3.916566 Cish 2.1771824 
Myd116 3.9051251 Apobec1 2.166548 
Nfkbie 3.8878582 4930599N23Rik 2.1636698 
Gadd45b 3.8755217 Casp4 2.1571677 
Tyki 3.8577104 D14Ertd668e 2.1451836 
Oasl1 3.6770806 Ch25h 2.1433632 
Hist1h2bf 3.6752925 Rhob 2.1350336 
Map3k14 3.601361 Stat1 2.099436 
Hist1h2bc 3.5996723 AA467197 2.0968196 
Irf9 3.5742452 Adar 2.0962126 
Oas1b 3.5114527 Zfp119 2.0928428 
Hist1h2bm 3.499247 Birc2 2.0871625 
Hist1h2bn 3.4989486 Dusp6 2.0710497 
Taf15 3.478466 Hist1h2bg 2.0666418 
Ifit2 3.4701445 Fbxw17 2.065485 
LOC100047963 3.4637952 Trex1 2.0468059 
Nfkbia 3.3646343 Trib3 2.0466084 
Gadd45g 3.3426063 Bhlhb2 2.0411756 
Ifit2 3.3320348 Rbm43 2.0352569 
Hist1h2bk 3.3153229 Edn1 2.0242689 
Clec2d 3.2698836 Pim3 2.0188584 
Hist1h1c 3.1748059 Arc 2.01379 
Oas1b 3.1642835 Hist1h2be 2.0041735 
Stat1 3.1558104 Napb 2.000367 
Errfi1 3.155 
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Figure 1. Poly I:C stimulation is associated with the induction of IFN-β and pro-
inflammatory and antiviral gene targets. Following poly I:C stimulation for four hours, 
RNA was isolated from MEFs and quantitative PCR was performed. Shown is the fold 
induction above unstimulated cells, normalized to hypoxanthine-guanine 
phosphoribosyltransferase (HPRT). Error bars represent variance of data from three 
independent transfections.  
 
 
with subsequent fixation and chromatin isolation. We then performed chromatin 
immunoprecipitation for several histone marks followed by next-generation sequencing. 
Transcriptional activation of poly I:C induced genes were notable for the accumulation 
of active histone marks at induced but not random promoters (Figure 2). Specifically, 
inducible genes showed substantial increases in H3K4me3, H3K9ac, H4ac, and Pol II.  
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Figure 2. Transcriptional activation by poly I:C is accompanied by dynamic changes in 
histone marks at promoters. ChIP-sequencing was performed with integrated profile 
plots generated corresponding to the average Pol II / H3K36me3 / H4ac / H3K9ac / 
H3K4me3 signal (in FPKM, as indicated) among either the 113 poly I:C-induced or 113 
random genes in the region +/- 5 kb from the transcriptional start site.  
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We observed in our data that dynamic regions also occurred outside of promoter 
regions. Specifically, our examination of the poly I:C-induced chromatin changes at the 
Ifnb and Ccl5 loci yielded a few noteworthy regions that displayed similar accumulation 
of active acetylated histones not present prior to stimulation. We suspected these 
regions might correspond to regulatory elements, which prompted sequencing for both 
H3K4me1 and p300 – both of which are found in regulatory regions. Indeed, we found 
that the vicinity of Ifnb and Ccl5 is populated by areas of dynamic chromatin that bear 
enhancer features (Figure 3).  
 
Figure 3. Histone marks are dynamic at the enhancers of inducible genes. ChIP-
sequencing tracks corresponding to the antibodies listed on the left; blue rectangles 
denote areas of H3K4me1 and p300 enrichment in the absence of H3K4me3 indicative of 
a putative enhancer region. 
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In light of this finding, we turned our attention to the identification of enhancer 
elements throughout the genome, as defined by the presence of H3K4me1 and the 
absence of H3K4me3 (Heintzman and Ren, 2009). This revealed over 200,000 putative 
regulatory elements in the mouse genome, of which approximately 22,000 were 
simultaneously bound by the transcriptional coactivator p300. Among this set of global 
distal regulatory elements, we sought to identify those enhancers activated in the 
innate immune response. We first employed an unbiased approach to find enhancers 
displaying dynamic regulation; using a two-fold cutoff, we detected 632 enhancers with 
an increase in H3K9ac, 869 with an increase in H4ac, and >2000 with an increase in Pol II 
binding. The accumulation of permissive marks and RNA polymerase at enhancers 
suggested a transition among a subset to increased enhancer activity. Whether these 
regulatory elements displaying dynamic regulation were in any way associated with poly 
I:C-induced genes was unclear – despite having noted proximity of these elements in the 
case of Ifnb1 and Ccl5. 
 
We therefore took an alternate approach to dynamic regulation of chromatin 
modifications at enhancers by first identifying those enhancers ‘belonging’ to poly I:C-
induced genes. This required an appropriate assignment of enhancers identified in 
sequencing data to annotated genes. Recently, the Ren lab described genome-wide 
annotation of enhancer-promoter units (EPUs) as an improvement over previous 
attempts at assignment (such as those based on proximity or within blocks between 
insulators [CTCF-bound]) (Shen et al, 2012). We used mouse EPU data to identify all 
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enhancers to a given promoter and examined the dynamics of marks at enhancer 
chromatin. As before, this analysis revealed an accumulation of active histone marks 
such as H4ac and H3K9ac at the enhancers of poly I:C-inducible genes paralleling the 
events at corresponding promoters (Figure 4). 
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Figure 4. The transcriptional response to poly I:C is accompanied by broad activation 
of the enhancers of transcribed genes. ChIP-sequencing was performed with integrated 
profile plots generated corresponding to the average H3K4me3 / H3K4me1 / H3K27ac / 
H3K27me3 / Pol II / H3K36me3 / H4ac / H3K9me3 / H3K9ac signal (in fragments per 
kilobase of exon per million reads [FPKM], as indicated) among either the 113 poly I:C 
induced gene promoters (left column; TSS +/- 5 kb) or at the extragenic enhancers 
within the EPUs of these genes (right column; p300 peak +/- 3 kb).  
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When examined broadly among the enhancers of inducible genes, we did not detect a 
discernible reduction in repressive marks, such as H3K9me3 or H3K27me3. Furthermore, 
an observable increase in Pol II was observed, suggesting that these enhancers may be 
newly transcribed. In this way, we uncovered a transition to enhancer activity 
specifically among those regulatory elements within EPUs of newly transcribed genes. 
 
Given the accumulation of permissive chromatin modifications at this group of 
enhancers, we next asked if these changes were associated with enhancer transcription. 
Using strand-specific RNA-sequencing of ribosomal RNA-depleted RNA, we were able to 
quantify transcripts of enhancer RNA (eRNA). Enhancer RNA within EPUs of poly I:C-
inducible genes were also induced, whereas enhancers in random EPUs were not 
similarly activated (Figure 5). 
  
31 
 
 
 
Figure 5. Enhancer transcription occurs broadly as part of the response to poly I:C. (A) 
Strand-specific RNA-sequencing tracks showing the upregulation of transcripts at (+) 
strand enhancers (red boxes) and (-) strand enhancers (blue boxes). (B) Profile plots of 
RNA-seq FPKM integrated for all promoters and their corresponding extragenic 
enhancers (within EPU) for same entities as in Figure 4.  
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As has been described previously, these eRNA transcripts appeared to originate from 
the enhancer ‘center’, as defined by the p300 peak and the center of the H3K4me1 
region, and extend bidirectionally (Kim et al, 2010). We were also able to detect the 
upregulation of specific eRNAs by RT-qPCR using random hexamers to prime the reverse 
transcription reaction, as eRNAs are not necessarily poly-adenylated. We saw specific 
increases in the transcription of several eRNAs at enhancers in proximity to the Ifnb1, 
Ccl5, and Mx2  genes, but not at a control enhancer belonging to Actb (Figure 6).  
 
Figure 6. Dynamic enhancers frequently belong to dynamic genes. Fold induction in 
enhancer RNA (eRNA) levels with 4 hours poly I:C stimulation, as measured by RT-qPCR 
with random hexamers to prime the cDNA reaction (to detect non-polyadenylated eRNA 
species). Data shown reflect three independent experiments; Y-axis reflects fold 
induction over unstimulated cells. 
 
 
Recently, enhancers have been classified according to their functional status as active, 
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H3K27me3, and low levels of Pol II and eRNA (Calo and Wysocka, 2012). Intermediate 
enhancers are thought to be unmodified at both H3K27 and H3K9. We then asked if poly 
I:C-induced enhancers were active enhancers with increased levels of activity or 
intermediate/poised enhancers that have become active. To answer this question, we 
determined the presence or absence of H3K9ac/H3K9me3 and H3K27ac/H3K27me3 prior 
to stimulation to divide enhancers into active, intermediate, and poised groups. We 
observed that the majority of regulatory elements are active or intermediate by H3K27 
status, but are intermediate or poised by H3K9me3 status. This controverts previous 
data that suggested that enhancers cluster similarly when K9 and K27 status are used 
(Zentner et al, 2011). When divided into active/intermediate/poised groups, 
intermediate or poised (by H3K9) poly-I:C-induced enhancers were more dynamic than 
active (H3K9ac) enhancers (Figure 7). 
 
Figure 7. Poised and intermediate enhancers are more dynamic than active enhancers 
in the poly I:C transcriptional response. Integrated profile plots reflecting RNA-seq data 
for extragenic enhancers of inducible genes, divided on the basis of H3K9me3+ (poised), 
H3K9- (intermediate), and H3K9ac+ (active). 
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That these H3K9me3/H3K9- enhancers show dynamic gain of transcriptional activity with 
poly I:C suggested that enhancer activation in the innate immune response involves a 
transition between enhancer states rather than an increase in the activity of already 
transcribed enhancers. 
 
We next asked if enhancer activation was a broad feature of the innate immune 
response. MEFs were cultured as previously but stimulated with either 500U/mL 
recombinant IFN-β or infected with Sendai virus (MOI = 10). Both stimuli elicited a 
similar transcriptional response (data not shown); chromatin changes at promoters and 
enhancers were as seen with poly I:C.  
 
 
 
Figure 8. Dynamic chromatin changes at transcriptional start sites and enhancer 
centers can be observed in response to other innate immune stimuli. Integrated profile 
plots reflecting ChIP-seq data following IFN-β stimulation (4 hours) or Sendai infection (6 
hours) for the set of promoters and extragenic enhancers obtained from poly I:C 
stimulation. 
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Specifically, we observed both increases in H3K9ac and Pol II at promoters and 
enhancers (Figure 8) as well as increases in eRNA in the same group of EPUs of poly I:C-
inducible genes (Figure 9).  
 
 
 
 
Figure 9. Enhancer activation is a broad feature of the innate immune response. 
Integrated profile plots reflecting RNA-seq FPKM for the enhancers induced by poly: I:C, 
here showed before and after IFN stimulation (4 hours) or Sendai virus infection (6 
hours).  
 
These findings suggest that enhancer activation is indeed a broad feature of the type I 
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suggest that poised and intermediate enhancers are most transcriptionally dynamic in 
the innate immune response.  
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Stochastic activation of enhancers in the innate immune response 
 
In the foregoing section, we were able to determine that there are global changes to 
chromatin in the type I interferon response. These changes consist of the accumulation 
of active histone modifications and RNA Pol II at the promoters of activated genes and 
their associated enhancers, which are accompanied by corresponding increases in the 
presence of eRNA transcripts. These findings are based on analyses of large cell 
populations; however, cellular activation in the type I interferon response is known to 
be heterogeneous. 
 
We next sought to determine if stochastic activation of the IFN-β gene is accompanied 
by stochastic activation of enhancer transcripts. To this end, we generated MEFs from 
IFN-YFP reporter mice generated by the Locksley lab (Scheu et al, 2008). MEFs were 
immortalized and subsequently stimulated with poly I:C. Using single-color flow 
cytometry, we recapitulated stochastic IFN-β activation with about ~15% of cells 
positive for YFP expression (data not shown). We sorted these cells for YFP and detected 
10-fold greater IFN-YFP transcript in YFP+ cells as compared to YFP- cells (Figure 10). To 
eliminate the contribution of IFN-dependent IFN-activation, we blocked the effects of 
secreted IFN-β with the addition of the IFN receptor antibody. In the absence of IFN-β 
signaling, stochastic activation persisted with a 10-fold difference in IFN-β transcript 
between YFP- and YFP+ cells. (Figure 11). 
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Figure 10. Expression of IFN-β in response to poly I:C exhibits stochastic features. qPCR 
results of normalized IFN-β expression in IFN-YFP MEFs stimulated with poly I:C for the 
times indicated and sorted on the basis of YFP. Data shown are representative of four 
independent experiments with  Student’s T-test performed for analysis (***p<0.001). 
Figure 11. Stochastic activation of IFN-β occurs independently of the signaling effects 
of IFN. Quantitative PCR results showing normalized IFN-β expression in IFN-YFP MEFs 
either pre-treated with vehicle or anti-IFNαR antibody and stimulated with poly I:C and 
sorted on the basis of YFP expression. Data shown are representative of three 
experiments; Student’s T-test performed for statistical analysis (***p<0.001). 
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Having demonstrated that gene transcripts are heterogeneously activated in a minority 
of cells, we hypothesized that the enhancer transcripts we found upregulated by poly I:C 
(Figure 6) would be detectable primarily in YFP+ cells. However, using primers generated 
to detect specific inducible eRNA transcripts and RT-qPCR, we found that poly I:C-
induced eRNAs predominate in YFP- cells (Figure 12).  
 
Figure 12. Enhancer RNAs are also activated in a stochastic manner primarily in the 
cells that do not activate gene targets. Quantitative PCR was performed on IFN-YFP 
MEFS sorted following stimulation with poly I:C. Primers were designed against 
enhancers located either downstream (D) or upstream (U) of the gene listed. Data 
shown are representative of three independent experiments; Student’s T-test 
performed for analysis (**p<0.01; *p<0.05). 
 
Much to our surprise, this was reproducible with several eRNAs in multiple independent 
experiments. This result suggests that (1) eRNAs are short-lived, and may be rapidly 
degraded in cells that make productive gene transcripts, or (2) eRNAs never accumulate 
in YFP+ cells. To confirm these findings, we subjected isolated RNA to whole-
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transcriptome ribosomal-depleted RNA sequencing. Though target gene transcription 
was substantially higher in YFP+ cells, we again noted a greater abundance of related 
eRNAs in YFP- cells (Figure 13). Taken together, these findings suggested a stochastic 
activation of enhancers in a distinct subpopulation from that which responds with 
successful target gene activation. 
 
  
 
 
Figure 13. Widespread transcription of enhancers is detectable primarily in cells 
without gene activation. Integrated profile plots showing the eRNA detectable by 
strand-specific RNA-seq of extragenic enhancers in IFN-YFP cells either unstimulated 
(dotted lines) or stimulated and sorted into YFP- (dashed lines) and YFP+ (solid lines) 
populations. 
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In vitro modulation of JMJD2d in MEFs affects the magnitude of the innate immune 
response 
 
We observed in our chromatin analysis that the bulk of newly transcribed enhancers 
were H3K9me3 or H3K9-. While we saw greater inducibility in H3K9ac than in any other 
chromatin mark (other than Pol II), we suspected that this represented a transition of 
poised and intermediate enhancers to active ones, as these are the ones that become 
transcribed. This led us to believe that H3K9 demethylases could be implicated in 
enhancer activation in the innate immune response. We searched for H3K9 modifiers 
that were transcriptionally induced by poly I:C. No specific acetyltransferase was 
inducible (data not shown); however, we did see that the mRNA transcript of the 
histone lysine demethylase JMJD2d was induced 10-fold to the exclusion of other H3K9 
demethylases (Figure 14).   
 
Figure 14. JMJD2d is transcriptionally activated by poly I:C. Quantitative PCR was 
performed on MEFs four hours following stimulation with poly I:C; primers were 
designed to detect transcripts corresponding to each of the demethylase genes above. 
Data shown are the average of three independent transfections. 
42 
 
That JMJD2d was specifically upregulated in this context suggested a role for the 
enzyme in the innate immune response that we investigated further. 
 
To determine if JMJD2d has an effect on poly I:C-induced responses, we performed in 
vitro knockdown of JMJD2d in MEFs using specific siRNAs (generated by collaborators at 
Alnylam Pharmaceuticals). Following stimulation with poly I:C 48 hours after 
knockdown, we saw a ~50% reduction in IFN-β expression as compared to control siRNA 
(Figure 15), with a similar attenuation of expression seen with several interferon-
stimulated genes (ISGs).  
 
 
Figure 15. Knockdown of JMJD2d attenuates Ifnb1 and ISG activation in response to 
poly I:C. MEFs were transfected with either ctrl or JMJD2d siRNA for 48 hours and then 
stimulated with poly I:C. Shown are normalized expressions of the indicated genes at 
the indicated times after poly I:C stimulation. Data shown are the average of three 
independent transfections; paired T-test used for analysis  (*p<0.05; **p<0.01). 
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We analyzed RNA extracts by microarray analysis, which revealed a significant decrease 
in ~30% of poly I:C stimulated genes, suggesting a broad effect on the type I interferon 
response (Figure 16).  
 
 
 
Figure 16. JMJD2d knockdown has a broad impact on the upregulation of several 
innate immune response genes. (A) Heat map showing decreased gene upregulation 
with JMJD2d knockdown in the 113 genes induced by poly I:C. (B) Venn diagram 
showing the proportion of poly I:C inducible genes downregulated and upregulated by 
JMJD2d knockdown. Data shown are the average of 3-4 independent samples subjected 
to microarray. 
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We then sought to determine if overexpression of JMJD2d would have the opposite 
effect. Cell lines stably overexpressing JMJD2d were generated and stimulated with poly 
I:C; here we observed a significant increase in the expression of IFN-β (Figure 17). 
 
Figure 17. Overexpression of JMJD2d increases expression of IFN-β in response to poly 
I:C. Stable cell lines overexpressing empty vector (EV), FLAG-tagged JMJD2a, or FLAG-
tagged JMJD2d were stimulated with poly I:C and collected at the time points indicated. 
Shown is normalized Ifnb1 expression by qPCR. Data are representative of three 
independent experiments, with paired T-test used for analysis  (**p<0.01; ***p<0.001). 
 
Overexpression of JMJD2a did not have the same effect.  Together, our knockdown and 
overexpression data implicate JMJD2d as a modulator of the poly I:C-induced activation 
of IFN-β. 
 
To determine if these findings could be generalized to physiologic type I interferon 
signaling, JMJD2d knockdown and overexpression experiments were performed with 
subsequent virus infection. In response to infection with vesicular stomatitis virus (VSV), 
JMJD2d-knockdown MEFS expressed less IFN-β than control siRNA treated cells (Figure 
 ** 
 ** 
*** 
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18). Similarly, the response to VSV was moderately enhanced by the overexpression of 
JMJD2d (Figure 19).  
 
Figure 18. Knockdown of JMJD2d affects the IFN response to virus. MEFs were 
transfected with either control or JMJD2d siRNA and infected with VSV (MOI = 1). Cells 
were collected after 16 hours and RNA extracted; shown are the results of qPCR on 
triplicate infections where the Y-axis represents normalized Ifnb1 expression; student’s 
T-test performed for statistical analysis (**p<0.01). 
 
Figure 19. Overexpression of JMJD2d potentiates the IFN response to virus. Stable cell 
lines overexpressing empty vector (EV), FLAG-tagged JMJD2a, or FLAG-tagged JMJD2d 
were infected with VSV (MOI = 1). Cells were collected after 16 hours and RNA 
extracted. The Y-axis represents normalized Ifnb1 expression; shown are the results of 
qPCR on triplicate infections; Student’s T-test performed (no significant p-values). 
 ** 
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These findings also extended to the frequency of viral infection using fluorescently-
labeled virus. Knockdown and overexpression of JMJD2d conferred viral susceptibility to 
VSV-GFP and resistance to sindbis virus (with mCherry fluorophore), respectively (Figure 
20). Taken together, these findings confirm a robust role for JMJD2d in broader type I 
interferon responses. 
 
Figure 20. Viral susceptibility and resistance are conferred by knockdown and 
overexpression of JMJD2d, respectively. (A) MEFs were transfected with control or 
JMJD2d siRNA and infected with GFP-expressing VSV at the MOI indicated. After 16 
hours, cells were subjected to flow cytometry and the percentage of GFP+ cells were 
calculated. (B) Stable cell lines overexpressing empty vector or FLAG-tagged JMJD2d 
were infected with mCherry-expressing Sindbis at the MOI indicated. After 16 hours, 
cells were subjected to flow cytometry and the percentage mCherry+ cells was 
determined. 
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In vitro modulation of JMJD2d in MEFs impacts stochastic activation of IFN-β 
 
We next inquired if the effects of JMJD2d on IFN-β activation also extend to the 
stochastic features as well. Using the IFN-YFP fibroblasts described previously, we found 
that siRNA-mediated knockdown of JMJD2d decreased the percentage of YFP+ cells 
generated in response to poly I:C by approximately 30-50% (Figure 21). This finding was 
replicated across several time points, two different siRNAs, and multiple experiments.  
 
 
Figure 21. Knockdown of JMJD2d decreases the percentage of IFN+ cells in response to 
poly I:C. IFN-YFP MEFs were transfected with control or one of two JMJD2d-directed 
siRNAs and stimulated with poly I:C for the indicated times. Cells were collected and 
subjected to flow-cytometry to determine the percentage of YFP+ (IFN-expressing cells). 
Data shown are representative of three independent experiments.  
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We observed a similar phenomenon in the context of virus infection with substantial 
abrogation in %YFP+ cells following JMJD2d knockdown and subsequent infection with 
Sendai virus (Figure 22).  
 
 
Figure 22. Knockdown of JMJD2d decreases the percentage of IFN+ cells following 
infection with Sendai virus. IFN-YFP MEFs were transfected with control or one of two 
JMJD2d-directed siRNAs and infected with SeV for the indicated times. Cells were 
collected and subjected to flow-cytometry to determine the percentage of YFP+ (IFN-
expressing cells). Data shown are representative of three independent infections 
(conducted in parallel).  
 
 
 
In the case of poly I:C stimulation, overexpression of JMJD2d in IFN-YFP cells yielded the 
opposite result, with an increase in the percentage of YFP+ cells by approximately 25-
50% (Figure 23).  
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Figure 23. Overexpression of JMJD2d increases the percentage of IFN-producing cells 
in response to poly I:C. Stable cell lines overexpressing empty vector, JMJD2a, or 
JMJD2d were stimulated with poly I:C and subjected to flow cytometry at the times 
indicated. Data reflect the average of three independent transfections with paired T-test 
used for statistical analysis (*p<0.05, **p<0.01). 
 
 
Having shown a robust impact of JMJD2d on the frequency and extent of innate immune 
responses, we next asked what is required for the effect of JMJD2d. In previous studies, 
JMJD2d has been described as an H3K9me3 demethylase with enzymatic activity 
dependent on a critical histidine residue within its binding pocket (H192). We asked if 
this residue is important to our observed effects. To that end, we mutated the histidine 
residue to alanine (H192A) to determine if the effect of JMJD2d on type I interferon 
responses depends on its enzymatic activity. We subsequently overexpressed 
enzymatically-dead JMJD2d in MEFs and stimulated these cells with poly I:C. In contrast 
to wild-type JMJD2d, we found no effect on the frequency of IFN-β producing cells, 
suggesting the effect depends on the catalytic activity of the enzyme (Figure 24). 
   * 
 * 
   * 
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 * 
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Figure 24. The catalytic activity of JMJD2d is required for the effect of JMJD2d 
overexpression on the frequency of IFN-producing cells. Stable cell lines overexpressing 
empty vector, JMJD2a, JMJD2d, or JMJD2d with the H192A mutation were regenerated 
and stimulated with poly I:C and subjected to flow cytometry at the times indicated. 
Data reflect the average of three independent transfections; Student’s T-test performed 
for statistical analysis (**p<0.01; ***p<0.001). 
 
Interestingly, the magnitude of the change in the frequency of YFP+ cells with 
knockdown and overexpression in these experiments nearly recapitulated the change in 
the quantity of transcript (see Figure 16/17). Of note, the mean fluorescence intensity in 
both knockdown and overexpression experiments was equivalent between control 
siRNA and JMJD2d siRNA samples and empty vector, JMJD2A overexpression, JMJD2D 
overexpression and JMJD2D-H192A overexpression samples, respectively. This suggests 
a role for JMJD2d in determining whether or not a cell activates IFN-β and not the 
extent to which it is transcribed in each cell. This data raised the possibility of JMJD2d as 
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a factor that not only modulates the type I interferon response but also helps to 
generate its stochasticity. 
 
If JMJD2d positively contributes to stochastic IFN-β gene activation, it follows to reason 
that JMJD2d would be most enriched in IFN-producing cells. In our previous sorting 
experiments, we had observed increased IFN expression in sorted YFP+ populations, but 
lower levels of inducible eRNA. YFP- cells had high levels of eRNA but low levels of 
activated genes. We next asked which sortable population, if any, would display JMJD2d 
enrichment. Much to our surprise, YFP- cells displayed a substantial enrichment of 
JMJD2d (~5-fold higher than YFP+ cells) (Figure 25).  
 
Figure 25. JMJD2d is preferentially expressed in cells that have high levels of enhancer 
RNA but low levels of gene activation. Quantitative PCR results of normalized Jmjd2d 
expression in IFN-YFP MEFs stimulated with poly I:C for the times indicated and 
subsequently sorted for YFP expression. Data shown are representative of three 
independent experiments, with a Student’s T-test used for statistical analysis (**p<0.01; 
***p<0.001). 
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In fact, the inducibility of JMJD2d with poly I:C stimulation observed previously occurred 
entirely in the YFP- population, with little difference in JMJD2d expression between poly 
I:C-stimulated IFN-producing (YFP+) cells and unstimulated cells. This result persisted in 
spite of blockade of any effects of IFN-signaling with the IFN-receptor antibody (Figure 
26).  
 
 
Figure 26. Preferential expression of JMJD2d in YFP- cells occurs independently of the 
signaling effects of IFN. Quantitative PCR results showing normalized Jmjd2d expression 
in IFN-YFP MEFs either pre-treated with vehicle or anti-IFNαR antibody and stimulated 
with poly I:C and sorted on the basis of YFP expression. Data shown are representative 
of three experiments, with statistical analysis conducted using a Student’s T-test 
(***p<0.001). 
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At first glance, this constellation of results appears puzzling. JMJD2d displays a robust 
effect on the overall magnitude of IFN responses largely by affecting the percentage of 
responding cells which themselves are not enriched for JMJD2d. Because IFN responses 
are characterized by enhancer activation and JMJD2d upregulation is seemingly 
detectable only in YFP- cells, we postulate that both eRNA and JMJD2d upregulation are 
transient and necessary events required for IFN-β activation. What remains unclear is 
why both eRNAs and JMJD2d are lost in IFN-producing cells. 
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Knockout of JMJD2d does not reveal a clear phenotype 
 
Having implicated JMJD2d in control of stochastic IFN responses, we sought to 
determine if a JMJD2d knockout mouse would recapitulate the in vitro findings. In mice, 
the JMJD2d gene consists of two exons, only the second of which contains the protein 
coding sequence. We generated a conditional targeting strategy employing Cre 
recombinase technology with loxP sites flanking exon 2 (Figure 27).  
 
 
Figure 27. Targeting strategy for conditional knockout of JMJD2d. Exon 2 of mJMJD2d 
was targeted with insertion of a PGK/Neomycin antibiotic selection cassette and loxP 
sites as shown above. Probes were designed for Southern blotting as indicated by S2 
and S3 probes in tan and green, respectively.  
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Following successful targeting, recombinant clones were confirmed by Southern blot 
analysis (Figure 28). After generation of JMJD2dfloxed/floxed mice, two different Cre lines 
were used to delete in various cell types. Specifically, EIIA-Cre was used to generate 
germline knockout mice (JMJD2d-/-) from which MEFs were derived and Vav-Cre was 
used to generate conditional deletion in hematopoietic cell lineages.   
 
 
Figure 28. Evaluation of JMJD2d targeting by Southern blot. Genomic DNA was 
digested with Hind III. Using the S2 probe, 3.8kb and 10.7kb products corresponding to 
targeted and wild-type alleles, respectively, were identified. Clones were numbered 
#129 and #134 and were used to generate JMJD2d-/- mice used in the subsequent 
analysis. 
 
 
JMJD2d-/- MEFs were isolated cultured, and immortalized as described previously. We 
confirmed the absence of any JMJD2d transcript; however, they did not clearly display 
any difference in poly I:C-induced IFN expression (Figure 29). Of note, the MEF cell lines 
– derived from separate embryos – displayed considerable heterogeneity in the amount 
of IFN expressed before stimulation, which persisted after poly I:C was administered.  
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Figure 29. JMJD2d knockout MEFs do not display a consistent difference in poly I:C-
induced IFN-β activation. Three independently derived MEF lines corresponding to 
JMJD2d+/- (#2) and JMJD2d-/- (#6, #9) genotypes were cultured and stimulated with poly 
I:C for the indicated times. Shown is the normalized Ifnb1 expression. Data are from 
three independent experiments. 
 
 
In a similar fashion, JMJD2d-/- bone marrow-derived macrophages were stimulated with 
poly I:C; no difference in IFN-β activation was observed (Figure 30). JMJD2dfloxed/floxed 
Vav-cre+ mice were injected with Flt3 ligand to induce the maturation of splenic DCs. 
DCs were harvested and cultured and stimulated with poly I:C; in concordance with our 
other knockout data, no difference in IFN-β was elicited (Figure 31). Finally, JMJD2d-/- 
mice and age-matched littermates were injected with poly I:C. We again did not detect a 
difference in IFN-β accumulation in either the spleen or in serum (Figure 32). These 
experiments simply failed to extend the findings in MEFs with JMJD2d 
knockdown/overexpression to other cell types lacking JMJD2d entirely.  
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Figure 30. JMJD2d knockout macrophages do not display a consistent difference in 
poly I:C induced IFN-β activation. Bone marrow-derived macrophages from either 
JMJD2d+/+ (wt) or JMJD2d-/- (ko) mice were generated and directly stimulated on day 7 
with poly I:C (not transfected); shown is the normalized Ifnb1 expression after the times 
indicated. 
 
Figure 31. JMJD2d knockout splenic dendritic cells do not display a consistent 
difference in poly I:C induced IFN-β activation. Splenic dendritic cells (DCs) derived 
from either JMJD2dfl/fl (wt), JMJD2dfl/+ Vav-cre+ (het) or JMJD2dfl/fl Vav-cre (ko) mice 
were injected with Flt3-L were cultured and stimulated with poly I:C for the times 
indicated; shown is the normalized Ifnb1 expression. 
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Figure 32. Systemic injection of poly I:C in JMJD2d-/- mice shows no type I interferon 
signaling defect. Three to five mice of each indicated genotype were injected with 
either PBS or 200 μg poly I:C as indicated. with subsequent harvesting of peritoneal 
macrophages or splenocytes after 8 hours. Quantitative PCR was performed on isolated 
cDNA; shown is normalized expression of Ifnb1.  
 
The absence of IFN signaling effects with in vivo deletion of JMJD2D led us to be 
concerned that the findings with in vitro modulation of JMJD2d might represent non-
specific effects of siRNA-mediated knockdown and retrovirally-transduced 
overexpression plasmids. To rule out artifact in these experiments, JMJD2d wild-type 
and knockout MEFs were transfected with JMJD2d siRNA. We observed that wild-type 
and JMJD2d heterozygous MEFs displayed any attenuation of IFN-β expression, while 
JMJD2d-/- MEFs were resistant to the effects of JMJD2d siRNA (Figure 33). In other 
words, the effect of JMJD2d siRNAs on IFN responses required the presence of JMJD2d 
in the cell, making a non-specific or off-target phenomenon less likely. 
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Figure 33. The effects of JMJD2d knockdown on poly I:C-induced IFN-β activation 
require the presence of JMJD2d. Wild-type (B6), heterozygous (#2) and JMJD2d-/- MEFs 
(#6, #9) were  transfected with either control or JMJD2d siRNA and stimulated with poly 
I:C for 4 hours; shown is the normalized expression of Ifnb1. Student’s T-test performed 
for statistical analysis (***p<0.001). 
 
We concluded from the foregoing that JMJD2d modulation has a discernible, robust, 
and reproducible effect with a few caveats. First, it seems to be most defined in MEFs 
and does not occur in cells of other lineages. Second, knockout cells of the same type 
also do not display a relationship between JMJD2d and IFN-β – perhaps this is owing to 
compensation by another demethylase. Regardless, we concluded that JMJD2d 
modulation is indeed a specific phenomenon insofar as we observed the same 
phenomenon in multiple wild-type fibroblasts cell lines and not in those lacking JMJD2d. 
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Chapter III: Control of enhancer transcription by JMJD2d 
 
The impact of JMJD2d modulation on chromatin 
 
Heretofore we have described a central role for JMJD2d in the modulation of type I 
interferon responses in MEFs. This role apparently depends on the presence of a key 
histidine residue central to the enzyme’s demethylase activity, a finding that led us to 
search for a role for JMJD2d on chromatin. At the outset, however, we sought to 
exclude the possibility that JMJD2d has a non-chromatin substrate for which its 
enzymatic activity is required. To answer this question, we transfected luciferase 
reporter constructs conjugated to the IFN-β promoter (IFN-luc) or to an IFN-sensitive 
response element (ISRE-luc) into MEFs. This provided a non-chromatinized IFN-β 
substrate responsive to the same upstream signaling elements and transcription factors 
as the endogenous IFN-β gene, but without the chromatin context (including any 
H3K9me1/2/3). MEFs were transfected with JMJD2d-directed siRNA to mediate 
knockdown of JMJD2d mRNA, followed by transfection of either luciferase reporter 24 
hours later. These cells were subjected to poly I:C stimulation with subsequent 
quantification of luciferase expression. We observed that siRNA-mediated knockdown 
of JMJD2d did not attenuate activation of the IFN- or ISRE-luciferase reporter in 
response to poly I:C (Figure 34), suggesting that the effects of JMJD2d depletion are not 
due to an impact on signaling.  
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Figure 34. Chromatin is required for the effect of JMJD2d knockdown on poly I:C-
induced IFN-β expression. MEFs were transfected with either control or JMJD2d siRNA 
as indicated, then transfected 24h later with either an IFN-luc or ISRE-luc reporter (non-
chromatinized). Cells were stimulated 24h later with poly I:C and luciferase expression 
was measured; normalized firefly luciferase expression (using Renilla as control) is 
shown. 
 
We conclude that JMJD2d is a positive regulator of IFN responses whose effect requires 
the presence of chromatin. Because type I interferon responses feature dynamic 
changes to chromatin leading to enhancer activation, we asked if JMJD2d knockdown 
interfered with these epigenetic events. MEFs were transfected with either control or 
JMJD2d-directed siRNA and stimulated with poly I:C 48 hours later. Cells were fixed and 
chromatin prepared for sequencing as described previously. Consistent with the broad 
effect on gene expression described previously, we observed a reduction with JMJD2d 
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knockdown in the amount of H3K4me3, H3K9ac, H4ac, and Pol II at the 107 poly I:C-
induced genes (Figure 35). While the overall magnitude reductions in each of these 
chromatin marks with JMJD2d knockdown were quite small, this result was highly 
significant given the number of genes integrated into each curve.  
 
Figure 35. Diminished accumulation of active marks at promoters induced by poly I:C 
with JMJD2d knockdown. Integrated profile plots showing the average enrichment of 
the indicated marks by ChIP-sequencing in MEFs at promoters induced by poly I:C. 
Chromatin was harvested from cells  treated with control or JMJD2d siRNA and 
stimulated with poly I:C. 
 
The reduction of active histone modifications and Pol II was reflected in decreased 
transcription of poly I:C-induced genes in JMJD2d knockdown cells, as determined by 
RNA-sequencing (Figure 36). No reductions with JMJD2d knockdown in either chromatin 
marks or RNA transcripts were detected in a set of 107 random genes (data not shown).  
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Figure 36. JMJD2d knockdown leads to diminished antiviral gene transcription. 
Integrated profile plots showing the average FPKM by RNA-seq of poly I:C-induced genes 
after 4h stimulation following pretreatment with either control or JMJD2d-directed 
siRNA as indicated. 
 
These findings in the ChIP-sequencing data recapitulate what we previously described: a 
small but broad reduction in the expression of poly I:C inducible genes and active 
promoter marks typically associated with gene expression level. We next asked if similar 
differences could be observed at enhancer locations. Because our data pointed to a key 
role for dynamic H3K9 at enhancers in IFN signaling, we reasoned that JMJD2d 
knockdown might interfere with the accumulation of H3K9ac. Using our previous set of 
extragenic enhancers assigned to inducible genes, we found that JMJD2d knockdown 
did affect H4ac and Pol II accumulation at enhancers (Figure 37). 
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Figure 37. Altered dynamics of chromatin marks at enhancers also occurs with 
depletion of JMJD2d. Integrated profile plots showing the accumulation of the indicated 
marks as detected by ChIP-seq in MEFs at extragenic enhancers induced by poly I:C. 
Chromatin was obtained from cells stimulated with poly I:C after either treatment with 
control or JMJD2d siRNA.  
 
 
A much smaller effect was discerned for H3K9ac, but this was magnified by restricting 
the group of extragenic enhancers to a smaller set in which poly I:C stimulation resulted 
in an H3K9ac increase (Figure 38). In other words, H3K9ac was induced to a lesser extent 
at enhancers in the setting of JMJD2d depletion. 
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Figure 38. Diminished H3K9ac accumulation at enhancers that normally induce H3K9ac 
in the poly I:C-induced transcriptional response. Integrated profile plots showing the 
accumulation of H3K9ac and H3K9me3 at extragenic enhancers in MEFs stimulated with 
poly I:C following pretreatment with control or JMJD2d siRNA.  
 
 
We next asked if poly I:C-induced extragenic enhancers display altered transcription 
with JMJD2d knockdown. Using ribosomal-depleted RNA sequencing, we observed a 
small but perceptible reduction in eRNA transcripts with JMJD2d knockdown (Figure 39). 
This reduction occurred primarily among the transcripts that displayed H3K9ac 
inducibility with stimulation, suggesting that JMJD2d only affects those enhancers that 
are dynamic at lysine 9. In order to validate this result, we designed primers for key 
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inducible enhancers in the type I interferon response and performed qPCR for these 
eRNAs.  
 
 
Figure 39. Diminished enhancer transcription is most notable among extragenic 
enhancers that induce H3K9ac. Integrated profile plots showing the FPKM of RNA 
transcripts as measured by RNA-seq in MEFs stimulated with poly I:C following 
pretreatment with either control or JMJD2d siRNA. All induced extragenic enhancers 
(left panel) and the subset of H3K9-inducible extragenic enhancers (right panel) are 
shown. 
 
 
Specifically, we found that JMJD2d knockdown significantly diminished eRNA expression 
at enhancers downstream of Ifnb1, Ccl5, and Mx2 without affecting any control 
enhancers at Actb (Figure 40). 
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Figure 40. Enhancer RNA transcription is attenuated by the knockdown of JMJD2d. 
Quantitative PCR showing the reduction in detectable enhancer RNA transcripts with 
JMJD2d knockdown in MEFs stimulated by poly I:C following pretreatment with either 
control or JMJD2d siRNA. Student’s T-test employed for statistical analysis (*p<0.05). 
 
 
 
Our results clearly show a role for JMJD2d in chromatin dynamics as well as 
transcription at induced enhancers. Because JMJD2d is a H3K9 demethylase, we looked 
for a corresponding change in H3K9me3, typically found at either end of the enhancer 
region as defined by the area of H3K4 monomethylation. In multiple experiments, we 
       * 
       * 
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did not observe any consistent change in this ‘flanking’ H3K9me3, though enhancers 
with H3K9me3 were the most dynamic in terms of both new H3K9 acetylation and Pol II 
accumulation. We attribute this finding to one of two possibilities: (1) a change in 
H3K9me3 is in fact present, but ChIP-sequencing was not sensitive enough to elucidate 
it, or (2) no change in H3K9me3 occurs and that JMJD2d functions instead to maintain a 
demethylated lysine 9 to facilitate acetylation (from H3K9me1 or H3K9me2 species) 
rather than to actively transition fully inactive or poised H3K9me3 to an active state.  
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JMD2d is tightly associated with actively transcribed enhancers on chromatin 
 
To this point, we have described a role for JMJD2d in the control of type I interferon 
responses. JMJD2d affects the frequency of IFN-producing cells presumably by 
regulating the activation and transcription of enhancers. JMJD2d is most highly enriched 
in those cells that have high levels of eRNA; when cells transition from enhancer 
transcription to gene transcription, JMJD2d is reduced to resting levels. Despite this 
circumstantial data, we did not yet have evidence to directly implicate JMJD2d in the 
control of enhancer chromatin. We therefore asked – what is the chromatin occupancy 
of JMJD2d?  
 
We initially sought to perform ChIP-sequencing for endogenous JMJD2d in MEFs. 
Unfortunately, no commercially available antibody displayed any enrichment for 
JMJD2d in multiple immunoprecipitations; Western blot analysis using these antibodies 
failed to adequately detect endogenous JMJD2d (data not shown). As a result, we 
examined stable JMJD2d-3xFLAG overexpressing cell lines against empty vector controls 
to determine the occupancy of JMJD2d. Chromatin was prepared as before and 
immunoprecipitation was performed with Flag antibody coupled to magnetic beads. In 
genome browser alignments, we recognized a significant enrichment in JMJD2d at 
enhancer positions that was not present at promoters (Figure 41). Of note, the binding 
pattern of JMJD2d was relatively broad, occurring over multiple kilobases. Across the 
genome, we further noted substantial enrichment in FLAG signal in JMJD2d-3xFLAG 
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Figure 41. JMJD2d occupancy aligns with enhancer locations in the genome. Genome 
browser tracks showing the colocalization of JMJD2d (as detected by FLAG ChIP-seq) 
with p300 / H3K4me1 regions (blue boxes highlight (+) strand enhancers / red boxes 
highlight (-) strand enhancers) in regions surrounding the Ifnb1 and Ccl5 genes. 
 
Figure 42. JMJD2d is enriched at enhancer chromatin genome-wide. Integrated profile 
plots showing the enrichment of FLAG in JMJD2d-3xFLAG or empty vector (EV) MEFs at 
either promoters (left panel) or extragenic enhancers (right panel) as determined by 
ChIP-seq data. Data shown are representative of three independent experiments in two 
independently derived cell lines. 
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chromatin samples relative to empty vector samples primarily at enhancers and not 
promoters (Figure 42). We subsequently took great care in peak-calling using algorithms 
optimized for the broad-type enrichment that we observed (see Materials and 
methods). After setting a false-discovery rate to <2.5%, we identified 4821 discrete 
JMJD2d-binding sites throughout the genome in unstimulated JMJD2d overexpressing 
MEFs; of these binding sites, approximately 70% colocalized with enhancer positions, 
while only 19% overlapped with promoters (Figure 43). Of the top 1000 JMJD2d binding 
sites in the genome, 85% overlapped with enhancers. 
 
 
Figure 43. The majority of JMJD2d binding sites in the genome colocalize with 
enhancers. Pie charts showing the percentage of JMJD2d binding sites overlapping with 
promoters (red), enhancers (blue), or other chromatin regions (green) for all binding 
sites with FDR<0.25 (n=4821) (left) or for the top 1000 sites (right). 
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Given the strong association between JMJD2d and enhancers, we next asked if JMJD2d 
is specifically enriched at particular subtypes of enhancers (i.e. active, intermediate, or 
poised). By H3K27 status, JMJD2d-bound enhancers were more likely to be active rather  
than intermediate or poised. We suspected that JMJD2d might be bound to active 
(H3K9ac) or intermediate (H3K9-) enhancers rather than poised (H3K9me3) enhancers 
because the enzyme would be unlikely to be bound without having catalyzed its target 
residue. Consistent with this hypothesis, we found that active enhancers were much 
more likely to be bound by JMJD2d than either poised or intermediate ones (Figure 44). 
 
 
 
Figure 44. Active enhancers are more frequently bound by JMJD2d than poised or 
intermediate enhancers. Pie charts indicating the percentage of JMJD2d-bound (blue) 
or JMJD2d-unbound (red) enhancers belonging to extragenic enhancers of each type: 
active (H3K9ac+), intermediate (H3K9-), or poised (H3K9me3 within 7.5 kb of enhancer 
center) 
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This data suggests that JMJD2d remains bound to enhancers where it has presumably 
demethylated K9 lysine residues. This observation fits nicely with our previous finding 
that enhancers with inducible H3K9ac are the most impacted by JMJD2d depletion, 
given that H3K9 acetylated enhancers are those bound by JMJD2d. In other words, 
JMJD2d – a demethylase that appears to potentiate enhancer activity – localizes 
precisely on those enhancers that are most active. 
 
Next, we asked if the chromatin occupancy of JMJD2d also displays dynamic features. 
JMJD2d-3xFLAG-overexpressing MEFs were stimulated with poly I:C and chromatin 
prepared as described previously. After 4 hours of poly I:C stimulation, JMJD2d binding 
was substantially altered. Though JMJD2d remained bound primarily to enhancers, we 
found substantial changes to binding sites corresponding to the locations of enhancers 
of nearby induced genes, with many sites either gaining or losing JMJD2d occupancy 
(Figure 45). 
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Figure 45. The localization of JMJD2d is dynamic with poly I:C stimulation. Genome 
browser tracks showing the enrichment of FLAG in duplicate samples either before (top 
2 red tracks) or after (bottom 2 red tracks) poly I:C stimulation, in regions surrounding 
the Ccl5 (top) and Cxcl1/Cxcl2 (bottom) chromatin regions.  
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This provides another piece of evidence to support JMJD2d as an enzyme crucial to 
enhancer activation. If JMJD2d in fact participates in this process, we hypothesized that 
its binding would positively correlate with other marks of active enhancers, such as 
p300 and eRNA expression. Though we saw changes in the enrichment of p300 at a 
given enhancer accompanied by a corresponding change in the amount of JMJD2d, we 
could not identify a significant genome-wide correlation. But when we restricted our 
analysis to enhancers dynamic in the innate immune response, we saw a modest 
correlation (r = 0.57) between the change in p300 and the change in JMJD2d with 
stimulation (Figure 46).  
 
Figure 46. Mild correlation between the change in JMJD2d occupancy and the change 
in p300 enrichment with poly I:C stimulation. The changes in enrichment of JMJD2d 
and p300 at H3K9c-inducible extragenic enhancers between unstimulated and poly I:C 
stimulated samples was calculated and plotted as above. Shown is the Pearson 
correlation coefficient. 
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Because p300 is also a marker of enhancer activity, we suspected that enhancer 
transcription might correlate with JMJD2d binding, but no discernible correlation could 
be identified. 
 As we were unable to identify a strong genome-wide correlation between 
JMJD2d and enhancer transcription and p300 coactivator occupancy, we turned to a 
chromatin state model to parse out these relationships. Such analyses have formed the 
backbone of chromatin annotation of both human and Drosophila genomes, 
respectively (Ernst et al, 2011; Kharchenko et al. 2011). Specifically, using a hidden 
Markov model, we were able to identify 29 unique chromatin states that capture the 
complexity of chromatin profiles, using the combinatorial data provided by our set of 
ChIP-seq and RNA-seq data (Figure 47). Each state is defined by a relative enrichment of 
each of the marks used to train the data set. 
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Figure 47. Chromatin state analysis reveals JMJD2d strongly associated with enhancer 
chromatin. Multivariate hidden Markov model emission showing 29 chromatin states 
based on ChIP-seq for the marks as indicated on the left. Intensity of each box indicates 
the frequency with which each state is accompanied by a given histone mark. 
 
We pursued this type of analysis to capture the association between JMJD2d and 
regulatory elements and their associated marks with the greater precision and 
robustness as has been described. As in previous studies, our 29 states could be 
subdivided into those associated with promoters, enhancers, transcribed, or inactive 
states. We did not have here the data with which to parse out insulator states (i.e. CTCF 
ChIP-seq).  
  
In our analysis, we found that JMJD2d was most enriched in states 9, 21, and 26 and to a 
lesser extent in 5, 10, and 14. In keeping with our speculation, states 9, 21, and 26 were 
notable for higher enrichment of p300 than states 5, 10, and 14. More broadly, states 5-
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11 displayed enrichment of H3K4me1 without H3K4me3, suggesting these as potential 
enhancers. In these states, there are varying degrees of enrichment of p300, H3K9ac, 
H4ac, and H27ac – all markers of enhancer activity – with which the state enrichments 
of JMJD2d appear to closely correlate. JMJD2d was also notably largely absent from 
promoter/TSS states (1-3) and likely heterochromatin states (17-18, 27-28); this 
confirms the idea that JMJD2d is most highly associated with enhancer chromatin. 
Whereas genome-wide correlations could not be generated, these findings further 
reinforce our view that JMJD2d is a key regulator of enhancer transcription as its 
enrichment closely follows other markers of active distal regulatory elements. 
 
To this point, we have outlined a role for JMJD2d in the control of type I interferon 
responses. Our data points to an effect of JMJD2d modulation on gene activation that is 
accompanied by an impact on the activation of enhancers – both in terms of the 
accumulation of active chromatin marks and the upregulation of enhancer transcription. 
Because enhancer activation temporally precedes gene transcription and there is no 
upstream signaling defect, we argue that the effects seen with JMJD2d depletion and 
overexpression arise directly from its effect on enhancers, which is precisely where the 
enzyme is bound on chromatin.  
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JMJD2d associates with chromatin remodelers and DNA repair machinery 
 
Our final question is whether JMJD2d engages in its activities on enhancer chromatin 
alone or as part of multimeric protein complex. We hypothesized that JMJD2d would 
require interactors because its structure is unique among the Jumonji family of 
demethylases in that it lacks both PHD and Tudor domains that interact with methylated 
histones. Because JMJD2d lacks such structural domains with which to cooperatively 
engage both H3K9me2/3 and a second residue (say H3K4me1), we suspected that it 
would require binding partners to ‘find’ enhancers.  
 
Table 2. JMJD2d associates with several DNA repair proteins and histone remodelers. 
Mass spectrometry results indicating the most highly enriched peptides with at least 
four unique spectra following immunoprecipitation of JMJD2d using FLAG antibody. 
Protein Function Enrichment 
PARP2 ADP-ribosylase 11.53 
JMJD2D Histone demethylase 10.70 
RAD23B XPC complex 10.27 
RPS8 RPA & synthesome complexes 8.07 
LTV1 Ligase 7.61 
XRCC6 RAP1 complex 7.31 
RPS24 RPA & synthesome complexes 7.29 
AHCYL1 Homocysteinase 6.65 
XRCC5 RAP1 complex 6.18 
HIST1H2AD Histone 6.02 
SSRP1 FACT dimer subunit 5.55 
CBX3 Heterochromatin protein 5.55 
HIST1H4A Histone 5.37 
PNO1 RNA-binding protein 5.26 
EMD Nuclear membrane protein 5.22 
KLHL26 Unknown 5.20 
USP9X Transcription co-activator 4.94 
HIST3H2BB Histone 4.72 
RPA1 DNA-binding protein 4.69 
TSR1 Transcription co-activator 4.69 
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To determine if such interactors exist, we performed immunoprecipitation of JMJD2d-
3xFLAG with M2 beads followed by mass spectrometric (MS) analysis. Trypsin digests 
revealed several DNA repair proteins and chromatin remodelers, including FACT 
complex members (SSRP1, SUPT16H) and RAP1 complex members (XRCC5, PARP1) 
(Table 2). We confirmed by Flag-IP followed by Western blotting  that XRCC5 and PARP1 
immunoprecipitate with JMJD2d (Figure 48).  
 
Figure 48. JMJD2d appears to interact with PARP-1, XRCC5, and SSRP1. 
Immunoprecipitation of JMJD2d in stably transfected HEK293 cells using FLAG antibody 
followed by Western blotting as shown.  
 
 
Interestingly, PARP1 has been previously linked to enhancer binding through its DNA-
binding domains and appears to promote the recruitment of transcriptional coactivators 
(Kraus, 2008). Of note, PARP-1 interacts with enhancers in a sequence-specific fashion, 
suggesting the possibility that PARP-1 recruits JMJD2d to specific enhancer positions. 
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Because a clear model of the regulation of gene expression by PARP-1 has yet to be 
elucidated, the significance of the JMJD2d-PARP1 interaction remains unknown. 
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Chapter IV: Discussion 
 
In the last few years, there have been significant advances in our understanding of 
enhancer chromatin. We know now that distal regulatory elements are typically 
annotated with specific histone marks, such as the preponderance of H3K4me1 and the 
absence of H3K4me3. Enhancers also feature many of the same combinatorial histone 
marks initially described for transcriptional start sites and promoters, such as H4ac and 
H3K9ac. Indeed, the epigenetic landscape at enhancer positions closely mirrors that of 
promoters because they too are transcribed, with detectable enrichments of the RNA 
polymerase machinery and enhancer RNA transcripts. These findings have made clear 
that not all regulatory elements are equal; the pattern of histone marks and coactivator 
binding make some enhancers active and others inactive. As before, the active 
enhancers are frequently transcribed and feature ‘active’ histone marks, while poised 
enhancers are less commonly transcribed and can feature ‘repressive’ histone marks. 
Functionally, enhancers serve as platforms for the engagement of transcription factors 
and therefore serve to integrate upstream signal with downstream gene transcription. 
 
To date, little is known about how these enhancers and associated chromatin 
environments are controlled. Several studies have shown that transcription factors can 
‘license’ enhancers (‘pioneer’ factors) or bind cooperatively to enhancer chromatin. 
Moreover, the histone acetyltransferase complexes p300/CBP and Gcn5/PCAF likely 
modulate the acetylated lysine 27 and lysine 9 histones seen at active enhancer 
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chromatin. But the factors that modulate methylated histone marks at enhancer 
chromatin and determine the patterning of active versus poised are largely unknown, as 
are the natural dynamics of enhancer chromatin in transcriptional contexts.  
 
In the preceding analysis, we describe a novel role for the histone 3 lysine 9 
demethylase JMD2d in the modulation of enhancer activity in innate immune 
responses. We have shown that type I interferon signaling is typically characterized by 
the activation of enhancer transcription and the accumulation of acetylated histones at 
enhancers with poised enhancers being the most dynamic. JMJD2d is also induced in the 
response to poly I:C and is a positive regulator of the extent of IFN-β production and the 
frequency of IFN-β producing cells. At the level of chromatin, JMJD2d is found at 
enhancers, primarily those that are active, and its occupancy covaries with the amount 
of p300. Presumably, in its binding to enhancers, JMJD2d seems to have an effect on the 
induction of active histone marks at enhancers and on the extent of eRNA upregulation. 
Finally, the downstream effect on IFN-β production appears to require the catalytic 
activity of JMJD2d.  
 
Contemporaneous with our work, Zhu and colleagues published data supporting a role 
for H3K9me3 in the control of enhancer function. They showed that enhancer regions 
with flanking H3K9me3 regions were associated with inactive genes. Artificial targeting 
of H3K9 trimethylation at the Mdc and Il12b enhancer regions was able to abrogate 
TNF-α-induced expression of the Mdc and Il12b genes. Similarly, demethylation of 
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H3K9me3 by overexpression of JMJD2d permitted expression in fibroblasts. Their data 
point to a central role of H3K9me3 in repressing enhancer function and describe JMJD2d 
as an enzyme that can remove this repressive mark to permit expression of two genes. 
In their analysis, they find as we have that JMJD2d colocalizes with enhancers and 
suggest that the H3K9me3 serves to give cell-type-specificity to otherwise broadly 
functional enhancers (Zhu et al, 2012).  
 
Taken together, the constellation of findings in our work represents the first description 
of a histone demethylase that acts in the transition of enhancers from ‘poised’ to 
‘active’, as we show a role for JMJD2d in enhancer transcription and in subsequent gene 
activation. H3K9me3 demethylation – undetectable in our experimentation – is a focal 
chromatin event catalyzed by JMJD2d that allows for the acetylation of nearby histones. 
This acetylation leads to eRNA transcription by Pol II, which either by tracking or by DNA 
looping or by an unknown mechanism involving the transcript itself (perhaps acting as a 
scaffold) leads in turn to initiation of transcription or relief of proximal-promoter 
pausing at nearby genes. JMJD2d appears instrumental in this process, given that it 
tightly associates with enhancers, modulates their transcription, and is found in 
subpopulations of cells producing eRNA but not mRNA. Our data, in conjunction with 
that of Zhu and colleagues, provides a strong body of evidence to support a central role 
for JMJD2d in enhancer activation.  
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Stochastic features of JMJD2d and enhancer RNA transcription 
 
Our analysis highlights features of IFN-β that are unique to a non-deterministic system. 
As has been described by Maniatis and colleagues, IFN-β expression occurs in a minority 
of cells despite activation with a signal that ubiquitously enters and activates cells. The 
stochasticity observed in this system has been attributed to limiting levels of the 
upstream signaling molecules, such that overexpression of RIG-I and TRIM25 augments 
the percentage of cells responding to ssRNA and increases in MDA5 and IRF7 enables 
responses to dsRNA (such as poly I:C). In our studies, we observed an interesting ability 
of JMJD2d to positively regulate the frequency of IFN-producing cells. This suggests that 
JMJD2d might also be limiting, a notion reinforced by the consistently low levels of 
absolute transcript observed in MEFs. 
 
Interestingly, our cell sorting experiments revealed a series of unexpected findings. As 
expected, Ifnb1 transcripts were higher in YFP+ cells yet this was accompanied by a lack 
of enhancer RNA. On the other hand, enhancer RNAs, even those ‘belonging’ to the 
Ifnb1 locus, predominated in YFP- cells despite limited activation of target genes in 
these cells. The presence of eRNA upregulation in YFP- cells suggests that transcription 
factors are not limiting, because eRNA activity likely requires TF engagement on 
enhancer DNA prior to transcription. Instead, the presence of eRNA without mRNA 
suggests two possibilities: (1) enhancer transcription is simply noise unrelated to gene 
transcription or (2) stochasticity is imparted by a block between enhancer activation and 
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gene activation. As to the first possibility, our data suggests that JMJD2d positively 
regulates both enhancer transcription and downstream gene activation - making it 
unlikely that they are unrelated. Furthermore, there is quite a bit of data to support a 
correlation between enhancer activity and nearby gene transcription (Kim et al, 2010; 
De Santa et al, 2010). The second possibility – that of a block between eRNA and mRNA 
at the root of stochasticity – is an intriguing one. It suggests that the means by which 
eRNA and mRNA transcription are connected is the step at which the bulk of poly I:C-
transfected cells remain confined.  
 
What are the steps between eRNA activation and mRNA production? A variety of 
chromatin barriers need to be overcome in order to mediate this connection. One is 
looping of the DNA between enhancer and promoter, facilitating the dissemination of 
information encoded in the enhancer-proximal landscape to the promoter. This looping 
requires the actions of Mediator and cohesin (Ong and Corces, 2011), as well as the 
displacement of nucleosomes by chromatin remodelers. Recruitment and assembly of 
the transcription complex is another key step leading to mRNA transcription beginning 
with the docking of TFIID and the pre-initiation complex (PIC). Where the PIC is already 
formed, enhancer chromatin may still be necessary for the release of promoter-
proximal pausing that requires acetylation of H4K16 and multimeric engagement by 
bromodomain-containing proteins (BRDs). Any one of these molecular events may 
represent the key step at which YFP- cells in our system are blocked from becoming 
YFP+. That we can distinguish in our experimental model a set of cells able to generate 
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eRNA without subsequent mRNA is intriguing, as it is may serve as a tool to elucidate 
the precise sequence of events that bridges the two transcriptional events.  
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Enhancer specificity of JMJD2d 
 
Coupled with the phenotype we observed with JMJD2d modulation is a strong 
association of JMJD2d with enhancers on chromatin. One of the questions that emerges 
from this finding is what are the mechanisms that give JMJD2d its specific occupancy? 
 
JMJD2d itself differs the other Jumonji family demethylases insofar as it lacks both PhD 
and Tudor domains, both of which are modules that engage methylated histones. 
Without these domains, JMJD2d is restricted to engagement of histones via only its 
JmjN and JmjC domains and does not have the ability to participate in multivalent 
engagement of histones. Two distinct observations raise the likelihood that JMJD2d 
requires interacting proteins to mediate its binding to enhancers. First, H3K9me3, the 
residue that JMJD2d catalyzes, is present in heterochromatin and in gene bodies as well 
as enhancers. JMJD2d is excluded entirely from heterochromatin – though it is possible 
that compaction of this chromatin precludes JMJD2d binding. Transcribed gene bodies, 
however, are euchromatic and have significant H3K9me3 without JMJD2d, suggesting a 
layer of specificity. If JMJD2d has no interacting partners, it follows that it would be 
found ubiquitously on H3K9me3 territories, as it lacks any other domains for further 
discrimination. Second, JMJD2d is frequently bound to enhancers that lack H3K9me3 
altogether – approximately two-thirds of active enhancers in our analyses were engaged 
by JMJD2d – suggesting that there is a mechanism that maintains JMJD2d occupancy 
long after the presumed demethylation event. 
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Our immunoprecipitation experiments raise the possibility that JMJD2d interacts with 
histone remodelers such as SSRP1, a member of the FACT complex. FACT, however, is 
relatively ubiquitous and heretofore has been described as a chromatin remodeler that 
facilitates nucleosome exchange to permit passage of active RNA polymerase II through 
transcribed genes (Kwon et al, 2010). How such a protein may recruit JMJD2d to 
enhancers is unclear. Certainly, chromatin remodeling may be crucial to maintenance of 
open chromatin at enhancers, but there is no data yet to describe the presence of FACT 
in these regions. 
 
PARP-1, involved in the polymerization of ADP-ribose, is another candidate interactor 
that emerged in our analysis. Like SSRP1, PARP-1 localization in the genome has been 
primarily at transcribed promoters, where it localizes just upstream of the 
transcriptional start site (Kraus, 2008). No enhancer function or occupancy has been 
described to date. PARP-1, unlike JMJD2d, directly interacts with genomic DNA via an 
amino-terminal DNA-binding domain containing two zinc finger motifs, and appears to 
preferential bind to double-strand breaks or crossovers rather than specific sequence 
motifs.  
 
In the absence of clear interactors with JMJD2d, the most parsimonious explanation for 
how JMJD2d is recruited to enhancers is that it interacts with a protein that has 
enhancer specificity. Candidates would include transcription factors, as the underlying 
enhancer DNA will have the transcription factor-binding site (TFBS) in question, or other 
90 
 
coactivators that engage enhancers (such as p300 or GCN5).  Whatever the constituent 
members, JMJD2d likely is a subunit in a macromolecular complex that acts 
cooperatively to activate enhancers.  
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Cell-type specific activation of enhancers by JMJD2d 
 
In our analysis, we observed that the effects of JMJD2d on poly I:C-induced 
transcriptional responses were restricted to mouse embryonic fibroblasts (MEFs). Our 
attempts to extend the findings to macrophages and dendritic cells (DCs) proved futile, 
as did our efforts with systemic poly I:C injection in the JMJD2d knockout mouse. While 
the failure of these efforts might suggest that the knockdown and overexpression data 
might be artifactual, we had sufficient robustness imparted by the reproducibility of the 
data, the use of multiple siRNAs in multiple cell lines, and a specificity arising from the 
failure of the knockdown to have any effect in knockout cells. What might explain the 
absence of a phenotype in other cell types? 
 
In the work of Zhu et al., it was noted that the expression of the Mdc and Il12b genes in 
response to TNF-α is cell-type specific. The failure of these genes to be expressed in 3T3 
fibroblasts was attributed to the presence of H3K9me3-rich regions flanking the 
enhancers, which are absent in Mdc and Il12b DCs. Indeed, our analysis produced a 
similar finding with respect to the effects of JMJD2d; sequencing of multiple histone 
marks including H3K9me3 in macrophages showed an altogether different pattern of 
histone marks at enhancers (data not shown). Notable in our data was the relative 
absence of H3K9me3 at poly I:C-inducible enhancers in macrophages, suggesting a lack 
of any enzymatic substrate for JMJD2d to have a role. One might expect this finding, as 
macrophages and DCs are so-called ‘professional’ IFN-producers and should intuitively 
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lack barriers to antiviral gene transcription. As such, our JMJD2d knockdown 
experiments in macrophages and knockout experiments in macrophages and dendritic 
cells showed no effect, we believe, because enhancer chromatin in these cell types is 
not identical to that in MEFs.  
 
In a similar vein, our inability to recapitulate the IFN phenotype in JMJD2d-/- MEFs may 
be explained by a difference in steady-state chromatin landscape between JMJD2d-/- 
and wild-type cells. It is entirely plausible that JMJD2d-/- MEFs may have an altogether 
different patterning of histone marks dictated by the absence of the demethylase during 
differentiation. Alternatively, a different demethylase may compensate for the lack of 
JMJD2d. Chief among the potential explanations, it should be noted, is that the JMJD2d 
wild-type and knockout MEFs were generated from different embryos (rather than 
conditionally deleted in MEFs following isolation and generation); in our hands, different 
MEF cell lines derived from different embryos (and of the same genotype) produce 
different amounts of IFN that appears to be an inherent property of the line that 
perpetuates with passaging. Naturally, conditional deletion using an ERT2-Cre system 
post-derivation of the line would have been ideal, but our repeated efforts to delete 
JMJD2d with tamoxifen never yielded complete deletion of the floxed allele.  
 
To conclude, that the modulation of enhancer activity by JMJD2d was observed strictly 
in MEFs most likely reflects the cell-type specificity of enhancer chromatin. This bears 
directly on the likely settings in which JMJD2d would play a role. Specifically, JMJD2d 
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may function differently depending on cell type and signaling context; while 
macrophages and DCs may not have any defect in IFN responses, there are likely other 
transcriptional responses for which there would be cell-type specific control imposed by 
JMJD2d. For example, Zhu et al. describe the JMJD2d-dependency of Il12b and Mdc 
mRNA expression downstream of TNF-α in DCs. We suspect that myriad as yet unknown 
JMJD2d-dependent combinations of cell type and target genes exist, all controlled by 
JMJD2d, but as of yet unknown. 
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JMJD2d as a potential therapeutic target 
 
In vivo, cell type-specific responses are a consequence of lineage specification, which is 
dictated by gene expression, which is, in turn, the result of the interplay between 
promoters, insulators, and enhancers. As Ren et al. have shown, enhancers, more so 
than the target genes they activate, are cell type-specific. In their analysis of five 
different human cell types, chromatin modifications at promoters are cell-type 
invariant, while they are highly varied at enhancers. Given that underlying DNA 
sequences are the same, variations in enhancer chromatin may contribute greatly to  
cell-type heterogeneity. This means that all the properties of enhancer chromatin are 
likely to be fundamentally different from one cell to the next. The DNA, on the other 
hand, is likely to be exactly the same, absent a mutation. Molecular targets that control 
enhancer chromatin are intriguing then because they can be expected to behave very 
differently depending on the cell type. 
 
JMJD2d, as a modifier of enhancer chromatin, may be a compelling therapeutic target. 
Plainly, drugs targeting JMJD2d could be used to treat autoimmune disease, for 
instance, but not carry with it potential side effects as the enzyme has a limited or 
altogether different effect on other cell types. More broadly, the presence of other 
modifiers of enhancer chromatin unearths a resource of targets that may have precise 
effects in a limited number of cell type/signal combinations. One might suspect that 
therapeutics directed against enzymes with such circumscribed effects would have 
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excellent pharmacologic properties. Whether the possibilities exist for targeting JMJD2d 
or histone-modifying enzymes like it remains to be explored. 
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Chapter V: Materials and methods 
 
Cell lines and culture. MEFs were generated from d13.5 embryos from C57/B6, 
JMJD2d+/+, JMJD2d-/- and IFN-YFP mice by trypsinization of the embryonic body and 
culture of adherent cells. Immortalization was performed with SV40 latent T antigen 
administered via retroviral transduction. All MEFs were cultured in DMEM with 15% 
fetal bovine serum (FBS), 1% L-Glutamine (L-glut), 1% penicillin-streptomycin (P/S), 1% 
non-essential amino acids (NEAA), and 0.1% 2-mercaptoethanol (2-Me) (GIBCO).  MEFs 
from passage number 12-15 were used for all experimentation. Bone-marrow derived 
macrophages (BMDMs) were cultured in DMEM with 10% FBS, 1% L-glut, 1% P/S, 1% 
NEAA, 0.1% 2-Me and supplemented with 5 ng/mL IL-3 (Peprotech) and 5 ng/mL M-CSF 
(Peprotech). Splenic dendritic cells (DCs) were cultured in RPMI 1640 with 10% FBS, 1% 
L-glut, 1% P/S, 1% NEAA, 10mM HEPES, 1mM sodium pyruvate, and 0.1% 2-Me, 
supplemented with 100 ng/mL of Flt3-L (R&D Systems). 
 
Mice. C57Bl/6 mice were obtained from Charles River Laboratories. EIIA-Cre and Vav-Cre 
mice were obtained from Jackson Labs. IFN-YFP mice were obtained from Richard 
Locksley. JMJD2dfl/fl mice were generated in the Tarakhovsky laboratory by Georg 
Busslinger. All mice were bred onto a C57Bl/6 background and mice were housed under 
specific pathogen free conditions. Experimental protocols were approved by the 
Rockefeller University Institutional Animal Care and Use Committee. Genotyping was 
performed by overnight digestion of clipped mouse tails in tail lysis buffer (10 mM Tris-
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HCl pH 8.5, 200 mM NaCl, 5 mM EDTA pH 8.0, 0.2% SDS and 100 µg/ml Proteinase K 
(Roche)) and subsequent ethanol precipitation to isolate DNA. Primers used are 
summarized in Table 1.  
 
Isolation of bone marrow-derived macrophages. Six to ten week-old female JMJD2d+/+ 
and JMJD2d-/- mice were euthanized and bone marrow cells isolated from the femur and 
tibia of both hind legs by flushing with 1x balanced salt solution (1xBSS). Bone marrow 
cells were cultured for 7 days, with BMDMs subsequently collected on day 7 by serial 
pipetting after incubation in PBS containing 2% FBS and 5 mM EDTA for 15 min. Cell 
viability was determined using Trypan Blue exclusion in a Neubauer hemocytometer. 
BMDMs were subsequently cultured in medium as described above. 
 
Isolation of splenic dendritic cells (DCs). Six to ten week-old female JMJD2dfl/fl and 
JMJD2dfl/fl Vav-Cre+ mice were injected subcutaneously with 5 x 106 BL6-Flt3L cells to 
expand the splenic dendritic cell compartment. Mice were euthanized two weeks later 
and splenocytes isolated in 1x BSS following 0.375U/mL collagenase D (Sigma) digestion 
of splenic fragments. Cell suspensions were passed through a 100 μM cell strainer, 
followed by lysis of erythrocytes. Enrichment of CD11c+ cells was then performed with 
initial Fc receptor blockade using (5 μg/mL anti-CD16/CD32) followed by CD11c MACS 
beads (Miltenyi Biotec). Conventional DCs were further purified by cell sorting 
(FACSAria; BD Bioscience) by gating on the B220- CD11b+ CD11c+ mPDCA-1- population. 
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cDCs were subsequently cultured in medium as described above, with replacement of 
medium on day 4 and collection of non-adherent cells on day 9. 
 
Cell transfections and stimulations. All knockdown experiments were performed using 
the Lipofectamine RNAiMAX transfection reagent (Invitrogen) with siRNA delivered at a 
concentration of either 20 or 50 nM in serum-depleted medium (OptiMEM; Invitrogen) 
as per the manufacturer’s instructions. Reverse transfections were employed with cells 
added to preformed siRNA:lipofectamine complexes pre-incubated for 20 minutes. 
Subsequent cell stimulations or viral infections were performed 48 hours after initial 
siRNA knockdown. Reporter constructs were transfected using the Lipofectamine 2000 
transfection reagent (Invitrogen) according to the manufacturer’s instructions.  
 
MEFs were stimulated by transfection of 2 µg/ml poly(I:C) into the cells using 
Lipofectamine 2000 transfection reagent (Invitrogen) following the manufacturer’s 
instructions. Alternatively, MEFs were stimulated with 500 U/ml recombinant IFN-β 
(R&D Systems) for the indicated times. To block IFN-β-induced signaling, MEFs were pre-
incubated with 10 µg/ml IFNαR1 antibody (MAR1-5A3, eBioscience, catalogue number 
16-5945). 
 
Retroviral transduction. Retrovirus was generated by transfecting BHK cells (ATCC) or 
Phoenix cells (laboratory stocks) with 1-4 μg plasmid using the Lipofectamine 2000 
Transfection Reagent (Invitrogen). Supernatants were collected at 24 and 48 hours post-
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transfection and added to MEFs pre-cultured in six-well plates. Polybrene (Sigma) was 
added at a concentration of 8 μg/mL. Six well plates were then centrifuged at RT for 90 
min and incubated at 37°C overnight; efficiency of transduction was measured by flow 
cytometry 48 hours following spin infection. 
 
Viruses and viral infections. Viruses were obtained as follows. Stocks of GFP-expressing 
VSV (designated VSV-GFP M51R), mCherry-expressing Sindbis virus, as well as influenza 
A (Puerto Rico/8/34 (H1N1)), amplified in 8-day old embryonated chicken eggs and 
titered by plaque assay on Madin-Darby canine kidney cells) were kindly provided by 
Adolfo Garcia-Sastre. Wild type VSV Indiana serotype (San Juan), originally a gift from 
Milton Schlesinger, was grown and titered on BHK-21 cells as previously described (Bick 
et al., 2003).  
 
MEFs were infected with individual viruses with a multiplicity of infection (MOI)  
between 0 and 1 by diluting the virus stock in PBS containing 0.5% to 1% FBS. Infection 
was allowed to proceed for 1 h. After removal of the virus containing supernatant, cells 
were incubated in fresh medium. For detection of infected cells via FACS, cells were 
infected with a reporter virus that leads to the expression of GFP in the infected cells 
(VSV-GFP, sindbis-mCherry). Cells were analyzed for GFP or mCherry expression at the 
indicated times. 
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Plasmids and cloning. Plasmids expressing mJMJD2A and mJMJD2d were generated by 
cloning PCR- amplified constructs containing the endogenous Jmjd2a and Jmjd2d loci 
conjugated to 3xFLAG into the MigR1 plasmid backbone. MigR1-JMJD2d-3xFLAG was 
subsequently subjected to site-directed mutagenesis using the GeneArt kit (Invitrogen) 
to generated the MigR1-JMJD2d-H192A-3xFLAG plasmid. All plasmids were transformed 
into competent E.coli at 42°C and subjected to antibiotic selection. Overnight bacterial 
cultures were grown, plasmids purified via maxiprep (Qiagen), and quantified on a 
NanoDrop spectrophotometer (Agilent). 
 
Flow cytometry and cell sorting. For flow cytometry, cells were collected and fixed in 
PBS containing 1% paraformaldehyde and analyzed on a FACSCalibur flow cytometer 
(BD) using CellQuest software. For cell sorting, cells were collected and fixed in the same 
fashion but analyzed on a FACSAria (BD) cell sorter to divide into YFP+ and YFP- 
populations.  
 
Primers. Primers used for mouse genotyping are listed in Table 3. Primers used for 
quantitative RT-PCR are summarized in Table 4. JMJD2d, Mx2, IRF7, Ifit1, and Ifit3 
TaqMan probes obtained from Applied Biosystems  Primer for enhancer RNA qPCR are 
listed in Table 5. All forward and reverse primers were mixed to a final concentration of 
50 μM for qPCR primers and 20 μM for genotyping primers. 
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Table 3. Primers used for mouse genotyping. Indicated are the sequences of primers 
used in the genotyping of JMJD2d, EIIA-Cre, and Vav-Cre. 
 
 
 
 
 
 
Table 4. Primers used for mRNA RT-qPCR. Indicated are the sequences of primers used 
to detect transcripts as listed. 
 
HPRT F CTCCTCAGACCGCTTTTTGC 
HPRT R  TAACCTGGTTCATCATCGCTAATC 
Cxcl1 F1 CTTGAAGGTGTTGCCCTCAG 
Cxcl1 F2 GCACCCAAACCGAAGTCATA 
Cxcl1 R AGGTGCCATCAGAGCAGTCT 
Cxcl2 F1 GCCAAGGGTTGACTTCAAGA 
Cxcl2 R1 CTTCAGGGTCAAGGCAAACTT 
Cxcl2 F2 CTCCAGACTCCAGCCACACT 
Cxcl2 R2 AGGGTCTTCAGGCATTGACA 
IFN F TCAGAATGAGTGGTGGTTGC 
IFN R GACCTTTCAAATGCAGTAGATT 
Mx1 F GTGGTAGTCCCCAGCAATGT 
Mx1 R AGCACCTCTGTCCACCAGAT 
TNF F CCCCAAAGGGATGAGAAGTT 
TNF R CTCCTCCACTTGGTGGTTTG 
IL-6 F TGGGAAATCGTGGAAATGAG 
IL-6 R CCAGTTTGGTAGCATCCATCA 
 
 
  
JMJD2d F CATTCCCAGCACCCTAACAG 
JMJD2d R1 CTGGTCCTACACAGCCCAGT 
JMJD2d R2 AGGCCTGGAGCCACTTTATC 
EIIA-Cre F AAGGGCGCGAAACTAGTCCTTAAG  
EIIA-Cre R CGCATAACCAGTGAAACAGCAT  
Vav-cre F AGATGCCAGGACATCAGGAACCTG   
Vav-cre R ATCAGCCACACCAGACACAGAGAT  
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Table 5. Primers used for eRNA RT-qPCR. Indicated are the sequences of primers used 
to detect enhancer RNAs as listed. 
Ifnb1 D1 F TCAAAGAAGGGCACCACCTA 
Ifnb1 D1 R GTGCTGGAGGAAGGAACAACT 
Ifnb1 D2 F ACTGCACGCAGAGAGGTTTC 
Ifnb1 D2 R GGAGGTAACTGGTTGCACTGA 
Ifnb1 U1 F CCATCCTGTCCCTGACAGAC 
Ifnb1 U1 R ATGAACGAGAAAGCAGCTGTG 
Ifnb1 U2 F TAGAACAAACGGGGCAAAGA 
Ifnb1 U2 R AGATCCTGCAGTTGTGCTCAG 
Ifnb1 D3 F  TTCAAACATTGGCCATCTGA 
Ifnb1 D3 R  CAAGACTGAGGGTGCGTATGT 
Mx2 U1 F ATCAGAGCACTGGGTGTCATC 
Mx2 U1 R TGGTTCCTGGCATACAATGTT 
Mx2 U2 F ACCCTTCCACCCATCCTCTA 
Mx2 U2 R TCCTTGCCTCTGCAGTGTTT 
Ccl5 U1 F CCAACCACATTCAGACCAGAG 
Ccl5 U1 R TCAGAGAGCAAGTGGGTGTG 
Ccl5 U2 F ACCTCTGGGACAGCAAGTAGC 
Ccl5 U2 R AGGGCAGGCAACTAGAGACA 
Ccl5 U3 F CCATGGTCACAGGGTAACAAC 
Ccl5 U3 R CCCAGCCCTTGCTTGTATTA 
Ccl5 U4 F  TGCCTGTCTCTGCAACAAGA 
Ccl5 U4 R  AACCCCCTGACTCCACCTAC 
Cxcl1 U1 F  GGCCACAGCTTCATTAAAACA 
Cxcl1 U1 R  AAAGTGGAATCCTGGGAGACA 
Cxcl1 U2 F  CATTCAACCTCAGTCCCATGA 
Cxcl1 U2 R  TTGTCACAGATCCGGAGAAAG 
Ifitm3 D1 F  GGAATGGAAGATGGGGAACT 
Ifitm3 D1 R  CTTCCACTTAGCCCCAGTCA 
Ifitm3 D2 F  AGCCGCAGTTTTATCCATCAT 
Ifitm3 D2 R  TCAATTCACTCGCCTTCACA 
Irf1 U1 F  AAGGAAAAGAGCGAGCAAAGA    
Irf1 U1 R  CCTGGACCTCAGGATCTTCTC 
Irf1 U2 F  TGCGTGCCATGAGATACAAG 
Irf1 U2 R  AACTGAAGGGACAGGCAGTG 
Actb U1 F ACGGAAGGGAAAGGAAAGAA 
Actb U1 R CCCCAGACAGTTACCACACAA 
Actb U2 F AAAACAAGCCAGGCACACAT 
Actb U2 R TAGCTGCCCTGGAACTCACT 
Actb U3 F  TCTCTCCAGGCCCTGTTAAGT 
Actb U3 R  CCTCTCGAGTGCTGGGATTA 
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Quantitative reverse-transcribed PCR. RNA was isolated with the RNeasy mini kit 
(Qiagen) or by the High Pure RNA isolation kit (Roche) and subsequently quantified  
using the NanoDrop 8000 spectrophotometer (Agilent). RNA was reversed transcribed 
using the Transcriptor First Strand Kit (Roche). qPCR was carried out using SYBR Green 
and products were quantified with a standard curve. Gene expression was displayed 
relative to Tbp or HPRT or GAPDH as indicated. 
 
Microarray analysis. 1-5 μg of total RNA from 2-3 MEF samples per group was used to 
prepare biotinylated RNA using the Ambion Illumina TotalPrep RNA Amplification Kit 
(Applied Biosystems) according to the manufacturer’s instructions. This RNA was 
hybridized to Illumina MouseRef-8 v2.0 expression BeadChip kits, with chips then 
scanned using the Illumina BeadArray Reader followed by analysis using Genespring 
(Affymetrix). The raw expression data was quality assessed and subjected to background 
adjustment and quantile normalization. The individual gene expression levels were 
compared by using an unpaired Student’s T-test (P<0.05) and by pairwise comparison. 
 
Immunoprecipitation. HEK293 cells were stably transfected with empty vector (MigR1) 
or FLAG-tagged JMJD2d (MigR1-JMJD2d-3xFLAG) constructs. Immunoprecipitation was 
performed using M2 beads on a rotator overnight at 4°C. 
 
Southern blotting. DNA was electrophoresed on 0.8% (for genomic DNA) agarose gels 
and rotated in transfer buffer (0.6 M NaCl, 0.4 M NaOH) for 45 min. DNA was 
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transferred by upward capillary transfer onto Hybond-N membrane (Amersham) 
overnight. Blots were rotated in neutralization buffer [0.5 M Tris-HCl (pH 7.0), 1 M NaCl] 
for 15 min and crosslinked in a Stratalinker (Stratagene) on “auto” mode. 
 
Blots were incubated briefly in 2X SSC, and transferred into pre-warmed hybridization 
buffer [50 mM Tris-HCl (pH 7.5), 1 M NaCl, 1% SDS, 10% dextran sulfate, 300 ug/ml 
sonicated salmon sperm DNA] and pre-hybridized for 3 hours at 65°C. Probes were PCR 
amplified from BAC DNA and gel purified (Qiagen). DNA (50 ng) was labeled with 5 μL 
32P-α-dCTP using Ready-to-Go labeling beads (Amersham) and purified over 
ProbeQuant G50 spin columns per manufacturers protocol. Eluted DNA was boiled for 5 
min and iced for 5 min prior to addition to prehybridized blot. Hybridization was carried 
out overnight with blots subsequently washed in 2X SSC/0.1% SDS, 1X SSC/0.1% SDS and 
0.5X SSC/0.1% SDS, wrapped in clear plastic wrap and exposed to film (Kodak XAR). 
 
Antibodies. The following antibodies were employed: histone H3 antibody (Abcam, 
ab1791), Histone H3 (di methyl K9) antibody (Abcam, ab1220), ChIPAb+ Trimethyl-
Histone H3 (Lys4) (Millipore, 17-614), Anti-acetyl-Histone H4 antibody (Millipore, 06-
866), RNA polymerase II CTD repeat YSPTSPS antibody [4H8] - ChIP Grade (Abcam, 
ab5408), anti-histone H3 monomethyl K4 antibody (Abcam, ab8895), anti-histone H3 
acetyl K9 antibody (Abcam, ab4441) , anti-histone H3 trimethyl K9 antibody (Abcam, 
ab8898), anti-trimethyl-histone 3 (Lys27) (Millipore, 07-449), anti-histone H3 (acetyl 
K27) antibody (Abcam, ab4729), and anti-Flag M2 antibody (Sigma, F1804).  
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ChIP-sequencing. Briefly, cells were incubated as above and at the indicated times 
following stimulation or viral infection were treated with 1% formaldehyde for 10 
minutes. Fixation was terminated with the addition of glycine to a final concentration of 
0.125M. Cells were then washed serially with PBS/0.5% FCS and collected. Cells were 
then lysed to isolate chromatin and sonicated for 10-20 min (depending on cell type) 
using a Bioruptor (Diagenode). Fragmentation of sonicated chromatin to lengths of 200-
500 bp was confirmed by agarose gel electrophoresis. 
 
For immunoprecipitation, beads were prepared with 7-10μg of antibody coupled to M-
280 mouse or rabbit Dynabeads (Invitrogen) for 8 hours as per the manufacturer’s 
instructions. Beads were then washed with PBS/0.5% FBS on a magnet and 20-50μg 
sonicated chromatin was added and incubated overnight on a rotator. Following 
immunoprecipitation, beads were washed in modified RIPA wash buffer (50 mM HEPES-
KOH pH 7.6, 100 or 300 mM LiCl, 1 mM EDTA pH 8.0, 1% NP-40, 0.7% Na-Deoxycholate) 
and then in TE wash buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 50 mM NaCl). 
DNA was then eluted at 65°C for 40 min in elution buffer (50 mM Tris-HCl pH 8.0, 10 
mM EDTA pH 8.0, 1% SDS). Crosslinks were reversed overnight and protein and RNA 
were digested. For validation of ChIP-seq, subsequent purified DNA was analyzed via 
qPCR. 
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For ChIP-seq library preparation, blunt-end DNA was prepared using the End-It End 
Repair Kit (Epicentre), “A” bases were added using Klenow fragment (NEB), and 
adapters for sequencing (Illumina) were ligated using T4 DNA ligase (NEB). Adapter-
ligated DNA was then amplified using PE primers 1.0 and 2.0 (Illumina) and Phusion 
polymerase (ThermoScientific). Libraries were analyzed via agarose gel electrophoresis, 
a NanoDrop spectrophotometer, on an Agilent Bioanalyzer for integrity, appropriate 
size, and the presence of adapter dimers or primer dimers. Libraries were then loaded 
onto the Illumina HiSeq 2000 according to Illumina protocols. 
 
RNA-sequencing. RNA was isolated in TriZOL reagent (Invitrogen) and purified according 
to the manufacturer’s instructions. Purified RNA was quantified on a NanoDrop 
spectrophotometer (Agilent). Total RNA was depleted of small RNAs (miRNA, tRNA) 
using the cleanup protocol of the RNeasy Mini Kit (Qiagen) and again checked for purity 
on a Nanodrop and the Agilent Bioanalyzer. Ribosomal RNA was depleted from 10μg 
total RNA using the Ribo-Zero Magnetic Kit (Epicentre). Ribo-depleted RNA was then 
fragmented with subsequent synthesis of cDNA and strand-specific library generation 
using the Script-Seq V2 Kit (Epicentre) and the FailSafe PCR enzyme mix, both used in 
accordance with the manufacturer’s instructions. Libraries were then loaded onto the 
Illumina HiSeq 2000 according to standard Illumina protocols. 
 
Analysis of sequencing data. For all alignments, reads were aligned to the mm9 build of 
the mouse genome, downloaded from the UCSC Genome Browser. For ChIP-seq data, 
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reads were aligned at 36bp (H3K4me3 and RNAPII) or 51bp (all others), allowing for only 
unique alignments with 2 mismatches using Bowtie v0.12.7. Sequencing reads from 
replicate ChIP experiments were combined for final analyses.  For RNA-seq data, reads 
were 101bp and were aligned using Tophat v2.0. Reads were segmented to 25bp and 2 
mismatches were allowed. Junctions were supplied from RefSeq annotations. Peak 
calling was performed as follows: MACS v1.4 was used for peak calling for p300 and 
CCAT3.0 for all others. Suitable inputs or controls were used for all analyses. Scores 60 
and higher were used for MACS and FDR values of 0.05 or less were used for CCAT3.0. 
For profiling of ChIP-seq and RNA-seq data, reads were extended 100bp from the 3’ end 
to account for the expected size of the fragments and binned into 100bp windows. 
Windows upstream and downstream of indicated features were queried for 5kb, or the 
distances indicated. In libraries where the rate of duplication was high, duplicates were 
removed to avoid biasing profiles. Profiles are reported as reads per million mapped 
reads per bin/window size (100bp). Fragments-per-kilobase-per-million-mapped-reads 
values were calculated from alignment data for the intervals/peaks regions specified.  A 
pseudocount of 1 read per 100M aligned reads per kilobase was used to avoid division-
by-zero errors.  
 
Enhancer definition. To qualify as an enhancer, p300 peaks (with score 60 from MACS) 
were assessed based on the following criteria. A p300 peak could not intersect with a 
H3K4me3 peak called for any condition (L0/L4/2D0/2D4), could not be within 1kb of a 
RefSeq gene start site (TSS) or 2kb from the start site (TSS) of any spliced EST entries 
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downloaded from the UCSC genome browser, and must intersect with a H3K4me1 peak 
location from any of the conditions. Intragenic enhancers were defined as those p300 
peaks that passed these criteria that were contained within the transcriptional unit for 
RefSeq genes. Extragenic enhancers were those remaining enhancers that were not 
within 5kb of the transcription end site, to avoid strong RNAPII from biasing profiling 
signal. For eRNA profiling, additional filtering was performed to eliminate potentially un-
annotated genes, repetitive sequence or other problematic features. As the 
characteristic profiles of eRNAs are short, less than 2kb transcripts in the region 2kb 
downstream on the plus strand and 2kb upstream on the minus strand were considered. 
The following were excluded: any transcript for which the ratio of reads contained on 
the forward strand 2kb downstream of the p300 peak summit to reads on the minus 
strand 2kb upstream was more than 5; any transcript for which the signal in the region 
+2-4kb or -2-4kb was higher than 2kb immediately upstream or downstream (to 
eliminate potential long/genic transcripts); any high signal over 1 FPKM that constituted 
a small fraction of loci with an aberrantly high number of alignments potentially due to 
repetitive signal; any loci with homology to any ribosomal RNA sequence. Inducible 
enhancers were defined as follows: Enhancers were deemed to be induced if H4ac or 
H3K9ac peaks were found in the poly I:C stimulated condition using the respective 
unstimulated H4ac or H3K9ac library as a control, using CCAT3.0 with an FDR < 0.1. 
These peaks had to intersect enhancers that passed all aforementioned criteria.  
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Chromatin state analysis. ChromHMM was used to determine chromatin states. 29 
states were specified, with the indicated target samples being used. Proper control 
libraries were used. The software models potential states using a hidden Markov model 
to determine likely combinations of enriched regions. Enriched regions for each target 
are then assessed for the representation in the various potential chromatin states. 
Target regions, such as genes, enhancers and other genomic loci can then be queried to 
ascertain the predominant chromatin states present at those loci. 
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